前往化源商城

144-75-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:AR protein [Homo sapiens]
External ID: MDAN535
Protocol: Please refer to other AIDs 743042 and 743041 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the AR antagonist mode assay (AID 743042) and cell viability counter screen (AID 743041). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryAR ActivityAR Potency (uM)AR Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inconclusive agonistinconclusive agonistinactive0NCI
inconclusive antagonist (cytotoxic)active antagonist18.12455735-111.5015527active antagonist20.3992366-95.33077837NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist33.49145963-71.97733202active antagonist33.49145963-45.59717193SigmaAldrich
inconclusive antagonist (cytotoxic)active antagonist24.63773286-89.63619394inconclusive antagonist33.49145963-42.65251674NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist30.2961402-37.60775273NCI
inactiveinactive0inconclusive antagonistLabotest
active antagonistactive antagonist28.72548756-74.97879422inconclusive antagonist32.33061121-27.15821987NCI
active antagonistactive antagonist27.64399095-64.36631028inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)inconclusive antagonist33.49145963-64.79576401active antagonist32.7130197-37.67340069NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
inconclusive agonistinconclusive agonistinactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: MDAV150
Protocol: Tox21 Assay Protocol Summary:

MDA-kb2 AR-luc cells were dispensed at 3,000 cells/4 uL/well of culture medium into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 0% CO2 for 5 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 0% CO2 for 16 h. After 15.5 h incubation, 1uL of CellTiter-Fluor reagent (Promega) was added using a Bioraptr FRD to each plate for measuring cytotoxicity. The fluorescence intensity was quantified on a ViewLux plate reader (PerkinElmer, Shelton, CT) following 30 min incubation at 37C and 0% CO2.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002746821 uM-Replicate_1Activity at 0.0005960927 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.16 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.95 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.9341-4.0025-4.45586.8198-1.1644-4.92122.01380.18830.932-6.078-2.34493.01673.4002-5.54413.9341QC'd by NCIInactive04.50450.56978
Cytotoxic15.6421110.147982Complete curve; high efficacy-4.80572.72020.9603-107.6072.5408-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0-95.90644.73640.534-1.15171.49885.7269-3.13844.6023-2.5915.101-0.7039-0.1448-2.8091-85.7578-95.9064QC'd by NCICytotoxic26.603280.513740Partial curve; high efficacy-4.57513.1320.9819-78.1328
Inactive00.30.5018-6.6712640 0 0 0 0 0 0 0 0 0 0 0 0 0-4.483807.84125.0947-0.36850.9766-4.3547-0.66533.21310-2.6766-3.7672-6.3927-2.7561-4.4838QC'd by NCIInactive0
Cytotoxic33.491553.023520Single point of activity-4.47514.95490.9093-57.314-4.2905-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.2755-6.13-5.7216-6.0909-1.1322-4.0113-6.953-0.8667-0.5352-3.8081-2.7523-6.4736-0.2391-14.0348-4.1839-50.2755QC'd by SigmaAldrichCytotoxic33.491543.216120Single point of activity-4.47514.95490.9489-44.7217
Inactive03.06540.64480.20834.321840 0 0 0 0 0 0 0 0 0 0 0 0 0-18.894333.038234.043-6.70165.11124.24770.05467.51211.52441.08954.9424.91169.6713-8.8416-18.8943QC'd by NCICytotoxic33.491538.402820Single point of activity-4.47514.95490.832-38.6215
Inactive04.95490.7541-3.03628.540 0 0 0 0 0 0 0 0 0 0 0 0 0-1.65425.818611.123-2.6648-5.527-2.1108-0.7834-0.2795-1.3292-6.2801-5.9904-3.6693-1.3675-3.1321-1.6542QC'd by NCIInactive04.95490.3332-0.5
Inactive04.95490.84961.39232240 0 0 0 0 0 0 0 0 0 0 0 0 04.046617.94353.1030.41822.1955-0.17152.82353.96390.0788-0.239-2.58983.38281.79160.39744.0466QC'd by NCIInactive04.50450.9224-0.7305
Inactive03.51170.39273-1.695140 0 0 0 0 0 0 0 0 0 0 0 0 0 02.3532-0.7162-0.0074-1.51420.6742-1.9219-3.891-3.1053-2.3524-2.8619-0.949-1.1980.6682-4.74592.1422.3532QC'd by NCIInactive0
Cytotoxic31.2143.456620Single point of activity-4.50574.95490.7461-46.3321-2.8755-30 0 0 0 0 0 0 0 0 0 0 0 0 0-45.4236-23.2298-4.49953.3316-2.32112.1332-2.31951.5412-1.1787-5.146-0.56271.3154-5.0727-6.7293-45.4236QC'd by NCICytotoxic26.603238.826420Partial curve; partial efficacy-4.57513.1320.8519-40.8264
Cytotoxic26.603234.702920Partial curve; partial efficacy-4.57512.40640.9771-38.2666-3.5637-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.0555-4.6672-2.5088-5.4716-4.3602-4.1809-2.6891-4.1367-1.8067-1.3031-4.0865-2.8527-4.2279-4.8434-16.0218-31.0555QC'd by LabotestInactive03.06540.7575-18.2037
Cytotoxic31.2126.94420Partial curve; partial efficacy; poor fit-4.50574.95490.8037-24.9442-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-24.1210.59991.3585-0.3563-0.60562.1079-1.54786.16642.4623-1.89281.97841.18620.52481.7585-24.12QC'd by NCICytotoxic33.491527.372520Partial curve; partial efficacy; poor fit-4.47514.95490.8005-26.3725
Inactive01.62660.7987-19.85024.540 0 0 0 0 0 0 0 0 0 0 0 0 0-14.87519.4894-1.33438.71942.60745.36513.28525.9036.96833.64690.0211-0.04561.4841-14.2523-14.8751QC'd by NCIInactive0
Inactive047.36137.5196-7.3951-0.70231.14315.96320.48820.14911.02055.83171.3822-0.343410.53266.96547.3613QC'd by NCIInactive0
Cytotoxic31.2131.422720Single point of activity-4.50574.95490.8431-33.9227-2.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0-33.2689-9.9006-5.5288-1.4219-0.0243-6.7803-3.4216-2.11071.4914-3.4573-1.8023-3.3297-0.1019-0.8542-33.2689QC'd by NCICytotoxic33.491551.227920Single point of activity-4.47514.95490.8738-54.2347
Inactive048.1128-3.52191.60923.5704-3.05675.54251.1281.79473.9211.45843.09545.7098-1.1492.90538.1128QC'd by NCIInactive0
Inactive04.95490.54013-7.823740 0 0 0 0 0 0 0 0 0 0 0 0 01.1178-1.9427-14.01981.42342.61488.01592.12438.1348-0.05886.06141.26242.49191.59630.22081.1178QC'd by NCIInactive0
Inactive043.42253.6223-3.44319.3218-0.1732-0.80331.8093-2.39193.81192.1766-1.5835-1.20313.85931.62713.4225QC'd by NCIInactive04.95490.38771
Inactive04.95490.42743.5-1.818940 0 0 0 0 0 0 0 0 0 0 0 0 0 04.6673-1.0353-6.09910.1105-0.7736-1.0905-3.54160.56970.18692.2758-5.4321-2.2238-3.56285.220.99214.6673QC'd by ChembridgeInactive0
Cytotoxic27.815930.261720Partial curve; partial efficacy; poor fit-4.55574.95490.7703-27.76172.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-26.4681-2.20990.61468.7045-3.0357-3.4205-0.0515-0.023510.83455.83643.293.32762.2442-2.1893-26.4681QC'd by NCIInactive04.95490.7812-21.5734
Inactive04-7.12970.2395-3.92457.56442.93285.83127.2431-2.9052-0.36468.84164.56552.17381.58961.9706-7.1297QC'd by NCIInactive04.50450.5518-8.9683
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-CoV-2-cytotox-48hr
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 h at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin).
6. Incubation. Incubate at for 48h at 37C 5% CO2
7. Reagent. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
8. Incubation. Incubate for 15 min at room temperature.
9. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells without cells (media only control) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Cytotoxic2.511989.96385Complete curve; high efficacy-5.62.40640.9988-81.9638-1.10 0 0 0-81.02564.3424-26.1944-82.8623-81.0256QC'd by MedChem Express
Cytotoxic3.162394.537785Complete curve; high efficacy-5.54.50450.9999-94.32250.2153-1.10 0 0 0-94.7013-0.2373-13.1526-93.6408-94.7013QC'd by SIGMA
Cytotoxic2.818494.81785Complete curve; high efficacy-5.552.04790.9999-95.8221-1.005-1.10 0 0 0-95.0616-6.2542-35.3146-94.5292-95.0616QC'd by APExBIO
Cytotoxic2.818490.520785Complete curve; high efficacy-5.553.06540.9989-88.52072-1.10 0 0 0-86.88350-24.056-89.9601-86.8835QC'd by MedChem Express
Cytotoxic5.623496.974284Complete curve; high efficacy-5.254.0951-95.47421.5-1.10 0 0 0-95.85761.65590-94.7507-95.8576QC'd by SynKinase
Cytotoxic3.981196.100684Complete curve; high efficacy-5.44.50451-95.10061-1.10 0 0 0-94.91080.5692-4.2795-94.8159-94.9108QC'd by Tocris
Cytotoxic2.511977.656384Complete curve; high efficacy-5.62.04790.9997-80.7421-3.0858-1.10 0 0 0-80.0369-5.0715-39.0219-77.613-80.0369QC'd by Microsource
Cytotoxic7.943399.498683Complete curve; high efficacy-5.14.95490.9997-96.99862.5-1.10 0 0 0-96.8051.23063.5418-95.9316-96.805QC'd by MedChem Express
Cytotoxic7.079597.835883Complete curve; high efficacy-5.154.95490.9993-95.83582-1.10 0 0 0-95.644503.4249-95.1788-95.6445QC'd by Tocris
Cytotoxic7.079597.375183Complete curve; high efficacy-5.154.0951-97.37510-1.10 0 0 0-97.18070-0.6843-95.5282-97.1807QC'd by MedChem Express
Cytotoxic7.0795102.439983Complete curve; high efficacy-5.151.69240.9998-100.43992-1.10 0 0 0-96.76290-9.8984-85.0051-96.7629QC'd by MedChem Express
Cytotoxic7.079596.356883Complete curve; high efficacy-5.154.95491-96.35680-1.10 0 0 0-96.164400-95.5939-96.1644QC'd by MedChem Express
Cytotoxic7.079593.612783Complete curve; high efficacy-5.154.95491-93.61270-1.10 0 0 0-93.425800-92.8807-93.4258QC'd by MedChem Express
Cytotoxic8.912597.135783Complete curve; high efficacy-5.054.95491-97.13570-1.10 0 0 0-96.941800-94.9322-96.9418QC'd by APExBIO
Cytotoxic8.9125105.03483Complete curve; high efficacy-5.051.64360.9999-100.0345-1.10 0 0 0-94.72923.0536-3.9173-76.9038-94.7292QC'd by Glixx
Cytotoxic1091.303782Complete curve; high efficacy-52.18761-85.80375.5-1.10 0 0 0-84.12124.86462.5388-67.7158-84.1212QC'd by SIGMA
Cytotoxic1098.125282Complete curve; high efficacy-52.84730.9999-97.62520.5-1.10 0 0 0-96.850400-83.9555-96.8504QC'd by Cayman
Cytotoxic11.220293.877282Complete curve; high efficacy-4.952.40640.9998-92.87721-1.10 0 0 0-91.056100-72.1776-91.0561QC'd by Selleck
Cytotoxic0.891360.234867Complete curve; partial efficacy-6.053.51170.9985-93.1767-32.9418-1.20 0 0 0-93.5509-51.1212-90.8041-91.9137-93.5509QC'd by Selleck
Cytotoxic0.794356.680267Complete curve; partial efficacy-6.13.92950.9999-91.2497-34.5695-1.20 0 0 0-91.0675-40.2642-90.3425-90.8279-91.0675QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=ATPase family AAA domain-containing protein 5; AltName: Full=Chromosome fragility-associated gene 1 protein
External ID: ELG271
Protocol: Please refer to other AIDs 651632 and 651634 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the ATAD5 assay (AID 651632) and cell viability counter screen (AID 651634). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryATAD5 ActivityATAD5 Potency (uM)ATAD5 Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active agonistactive agonist19.3311819612.17977568inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0TCI
inactiveinactive0inactive0Alfa Aesar
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inconclusive antagonistinconclusive antagonist-22.16843258active antagonist30.63785869-80.36907549SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-CoV-2-PP
Protocol: PROTOCOL TABLE (format as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 hr at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of SARS-CoV-2-S pseudotyped particles. [a] PPs are produced with murine leukemia virus pseudotyping. [b] SARS-CoV-2-S is Wuhan-Hu-1 sequence (BEI #NR-52420) with C-terminal 19 amino acid truncation.
6. Centrifuge. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubation. Incubate at for 48 hr at 37C 5% CO2
8. Centrifuge. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Reagent. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubation. Incubate for 5 min at room temperature.
11. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-CoV-2-S PP as 100%, and wells containing bald PP (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Inhibitor0.707934.828810Complete curve; partial efficacy; poor fit-6.154.95490.7525-34.81130.0174-1.40 0 0 0-43.6793-3.7355-37.8905-22.6342-43.6793QC'd by MedChem Express
Inhibitor35.481336.764810Single point of activity-4.452.40640.8748-40.7648-4-30 0 0 0-31.8873-11.45960-6.0521-31.8873QC'd by Pharmaron
Inhibitor39.810740.392710Single point of activity-4.44.44950.7948-48.5731-8.1804-30 0 0 0-41.7275-5.1127-20.8986-3.4837-41.7275QC'd by FLUKA
Inhibitor39.810736.302110Single point of activity-4.44.44950.9302-39.3021-3-30 0 0 0-33.1684-8.76590-0.1246-33.1684QC'd by Prestwick
Inhibitor1091.825410Partial curve; high efficacy; poor fit-53.92951-91.32540.5-2.31 0 0 0-91.1431-30.0380-57.0259-91.1431QC'd by APExBIO
Inhibitor39.810788.872610Single point of activity-4.44.95490.9981-87.87261-30 0 0 0-75.3105003.3645-75.3105QC'd by Microsource
Inhibitor39.810739.07410Single point of activity-4.44.95490.9982-38.5740.5-30 0 0 0-32.9783001.4313-32.9783QC'd by Carbosynth
Inhibitor17.782845.659310Partial curve; partial efficacy; poor fit-4.751.96730.9887-54.3257-8.6664-2.40 0 0 0-50.2467-11.0836-6.8054-21.6158-50.2467QC'd by TargetMol
Inhibitor39.810774.978610Single point of activity-4.44.44950.9815-77.9786-3-30 0 0 0-65.3989-8.931700-65.3989QC'd by MedChem Express
Inhibitor39.810735.78810Single point of activity-4.44.44950.945-39.8408-4.0529-30 0 0 0-34.034-8.1712-5.8755-0.0441-34.034QC'd by Adooq
Inhibitor19.952698.547510Partial curve; high efficacy; poor fit-4.71.96730.9936-101.5475-3-2.30 0 0 0-90.5058-6.67020-28.4282-90.5058QC'd by MedChem Express
Inhibitor39.810794.209610Partial curve; high efficacy; poor fit-4.44.44950.9731-106.3898-12.1802-2.30 0 0 0-90.4675-6.8168-21.693-10.2877-90.4675QC'd by Axon Medchem
Inhibitor39.810768.339410Single point of activity-4.44.95490.8933-61.33947-30 0 0 0-51.53290021.3412-51.5329QC'd by MedChem Express
Inhibitor11.220245.057510Partial curve; partial efficacy; poor fit-4.951.85790.9996-42.55752.5-2.41 0 0 0-40.794-21.67980-20.0057-40.794QC'd by MedChem Express
Inhibitor22.3872113.332310Partial curve; high efficacy; poor fit-4.651.69241-111.33232-2.31 0 0 0-91.8583-33.87930-25.3979-91.8583QC'd by Microsource
Inhibitor7.079544.4210Single point of activity-5.154.95490.6152-48.42-4-30 0 0 0-44.8333-14.7954-20.3760-44.8333QC'd by SIGMA
Inhibitor39.810732.918510Single point of activity-4.44.95490.6127-36.9185-4-30 0 0 0-32.01542.7163-20.08280-32.0154QC'd by Selleck
Inhibitor39.810751.184410Single point of activity-4.44.44951-51.18440-30 0 0 0-42.6537000-42.6537QC'd by MedChem Express
Inhibitor1058.179910Partial curve; partial efficacy; poor fit-53.51170.9887-59.1799-1-2.40 0 0 0-59.8069-4.87472.0564-35.7833-59.8069QC'd by DC Chemicals
Inhibitor39.810740.290110Single point of activity-4.44.44950.7334-45.6865-5.3964-30 0 0 0-38.9054-16.4277-13.0282-1.1636-38.9054QC'd by Adooq
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:thyroid hormone receptor beta isoform 2 [Rattus norvegicus]
External ID: TRN186
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37 C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo Luciferase Assay reagent (Promega) was added to each well using a Bioraptr FRD (Beckman Coulter), followed by 30 min incubation at room temperature. The luminescence intensity of plates was recorded by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.0950.3471-11.4032.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.50250.1158-3.1697-0.33515.6720.861714.90173.38536.9176-0.23470.4322-0.26143.98420.0305-0.2471-9.5025QC'd by NCIInactive0
Inhibitor8.4127111.383Complete curve; high efficacy-5.07514.50450.9828-108.24563.0545-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-112.7558-1.15723.06639.00343.54455.92481.74539.42291.34811.146-12.38566.95031.0946-61.7744-103.2834-112.7558QC'd by NCIInhibitor11.8832114.52442Partial curve; high efficacy-4.92512.95230.9725-113.8942
Inhibitor33.4915108.428710Single point of activity-4.47514.95490.9805-106.41752.0112-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.3487-0.0130.29265.8092.3543-1.529-1.86081.7268-1.32142.07110.45466.4268-1.17365.0616-1.2831-93.3487QC'd by NCIInhibitor33.491545.255310Single point of activity-4.47514.95490.8805-44.8499
Inhibitor6.6824112.359884Complete curve; high efficacy-5.17512.72020.9976-112.35980-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-107.86851.8367-0.98520.055-0.0873-0.0192-0.22741.70630.4571-0.0314-1.0907-6.2723-21.2839-82.4952-110.1566-107.8685QC'd by SigmaAldrichInhibitor11.8832118.081443Partial curve; high efficacy-4.92511.80790.9544-118.7095
Inhibitor6.6824105.669684Complete curve; high efficacy-5.17514.95490.9938-106.8079-1.1383-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-105.07267.23320.2468-0.2504-1.5237-2.6002-3.7474-7.12-3.24092.46950.0289-2.5534-12.3799-89.7924-106.5947-105.0726QC'd by NCIInhibitor9.4392121.220283Complete curve; high efficacy-5.02513.990.9879-117.3663
Inactive01.39870.58200.743840 0 0 0 0 0 0 0 0 0 0 0 0 0 16.5615-1.2435-1.42584.69634.22561.3627-6.880211.4156-5.29793.471-0.63623.942610.207711.431217.98796.5615QC'd by NCIInactive04.95490.50497
Inactive048.6584-0.25360.6070.1862-7.14463.14683.8879-0.6670.72263.43975.19140.62353.6739-0.02550.89198.6584QC'd by NCIInactive00.80.38469
Inactive0410.54210.43950.42364.47171.1049-1.458613.91965.5002-1.05963.065-7.07060.06181.202510.164811.16310.5421QC'd by NCIInactive03.990.606418
Inactive04-2.79550.91070.63340.0441-1.57746.62466.8752-6.6198-1.914714.01640.09133.5513.40912.4192-0.0362-2.7955QC'd by NCIInactive01.82650.72117
Inhibitor29.849398.496140Partial curve; high efficacy-4.52512.58840.9136-98.06750.4287-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-74.29356.770611.4199-0.0327-7.65161.0084-7.6141-0.0057-4.1882-0.0137-5.30869.05936.513-11.2634-24.6953-74.2935QC'd by LabotestInhibitor23.710181.201341Partial curve; high efficacy-4.62511.62660.9814-85.328
Inhibitor11.8832113.855282Complete curve; high efficacy-4.92513.51170.9826-115.6541-1.7989-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-108.9022-2.57351.71220.0161-0.9518-6.581711.0269-0.7611-7.71670.0417-2.5311-7.3404-6.9128-34.9326-107.0686-108.9022QC'd by NCIInhibitor13.3332117.674582Complete curve; high efficacy-4.87513.1320.9752-119.5106
Inhibitor11.8832100.560342Partial curve; high efficacy-4.92512.30310.9844-98.40762.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.4781-3.68021.45591.078-0.28983.594211.15550.03471.61545.5371-0.609-0.03380.0197-37.731-72.8614-96.4781QC'd by NCIInhibitor11.8832104.835482Complete curve; high efficacy-4.92512.84730.9729-101.2413
Inactive049.109716.353612.83932.63922.84184.686310.95966.499811.73249.79221.807413.675211.786911.24189.60329.1097QC'd by NCIInactive04.95490.571320.5
Inhibitor9.4392111.014483Complete curve; high efficacy-5.02513.06540.9851-108.05722.9572-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-104.01842.36323.22810.98985.081712.35020.2029-2.0107-1.81368.62391.97771.5258-9.3399-43.8626-105.9384-104.0184QC'd by NCIInhibitor11.8832117.796983Complete curve; high efficacy-4.92513.51170.9855-119.6341
Inactive01.10.49998.50.760140 0 0 0 0 0 0 0 0 0 0 0 0 0 06.7333-1.17177.005-0.40612.2711-1.86660.092310.02274.12186.31389.59344.80676.54059.438813.04816.7333QC'd by NCIInactive03.51170.516322
Inhibitor23.710130.537110Partial curve; partial efficacy; poor fit-4.62514.44950.7197-30.53710-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.1975-0.68221.0324-2.45350.1458-0.1477-0.2161-13.6864-3.44241.79450.06561.3783.68649.5588-10.7074-29.1975QC'd by NCIInactive04.95490.9007-21.9629
Inactive0413.5114-0.54170.0115-0.029211.3153-0.00342.57815.33694.0109-1.29990.1952.6113-0.1351-0.43365.290313.5114QC'd by NCIInactive00.80.552326
Inactive040.5778-0.8927-0.3832-2.6058-1.17790.83535.6138-2.89484.8776-1.355-0.2164-10.3629-1.68473.3283-2.910.5778QC'd by ChembridgeInactive0
Inhibitor26.603248.396120Partial curve; partial efficacy-4.57514.95490.9177-49.2222-0.826-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.4351-2.3640.3688-9.6388-2.3442-2.041-0.00221.4733.1991-2.8675-0.6678-2.01651.02016.8251-11.741-46.4351QC'd by NCIInhibitor26.603240.019410Single point of activity-4.57514.95490.7816-36.0194
Inhibitor21.131779.094741Partial curve; high efficacy-4.67513.51170.7387-73.1775.9177-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.1538-0.9821-2.4893-8.8857-2.70951.21070.3298-0.1518-3.40975.743516.504521.713139.4410.1435-33.7222-68.1538QC'd by NCIInhibitor33.491568.810410Single point of activity-4.47514.95490.782-64.8654
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: TRV455
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.95490.51575.6094-10.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-27.8709-9.58131.553-23.1602-8.9484-8.346419.02864.562714.53951.15650.42210.27193.49757.10181.1664-27.8709QC'd by NCIInactive0
Cytotoxic11.8832114.332782Complete curve; high efficacy-4.92513.92950.9541-100.920113.4126-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.18524.113126.147419.56668.33238.270922.114823.359311.62112.5923-0.271521.57888.2783-15.4501-95.7853-95.1852QC'd by NCICytotoxic13.3332101.165782Complete curve; high efficacy-4.87513.51170.924-104.4065
Cytotoxic33.491569.601420Single point of activity-4.47514.50450.5249-51.740917.8605-30 1 0 0 0 0 0 0 0 0 0 0 0 0 0-39.633934.934439.865511.20360.12813.12894.307410.103240.163543.97149.337135.80113.21470.805410.5036-39.6339QC'd by NCIInconclusive10.590945.114210Single point of activity-4.97510.80.518447.3375
Cytotoxic8.412795.006983Complete curve; high efficacy-5.07511.96730.9579-102.9662-7.9593-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-94.1612-1.6767-10.7501-18.3328-8.44320.3012-1.3116-10.0891-5.1512-10.2638-22.1904-3.3436-24.9807-62.5458-94.2914-94.1612QC'd by SigmaAldrichCytotoxic11.883290.158242Partial curve; high efficacy-4.92511.59360.9327-91.6733
Cytotoxic7.497881.846383Complete curve; high efficacy-5.12512.33320.9281-89.6388-7.7925-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-91.0963-18.97671.8287-17.872-12.3952-7.6161-16.3335-2.8335-2.6272-3.7796-9.8936-2.6598-12.2011-70.0356-74.6023-91.0963QC'd by NCICytotoxic7.497889.379383Complete curve; high efficacy-5.12512.40640.958-91.4223
Inactive049.32249.077510.90740.011913.6377.6888-14.85723.0077-6.11470.1121-5.92519.31916.946521.403721.67069.3224QC'd by NCIInactive0
Inactive048.728114.5817-0.06687.0683-0.16080.00131.578912.1056-2.13575.0113.2012-0.24876.3162-7.20095.40878.7281QC'd by NCIInactive04.95490.3678-32.6446
Inactive01.96730.466926.51032.587640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.33589.20266.9567-7.84944.72089.308420.04687.737-11.6312.3017-13.68133.162210.305816.449622.830726.3358QC'd by NCIInactive03.06540.3751-0.4202
Cytotoxic26.603233.620Partial curve; partial efficacy; poor fit-4.57513.990.6032-35.6-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.1667-19.4025-0.1543-0.2262-0.0757-11.09324.6638-6.5718-3.54455.09010.036-2.1840.10135.1383-12.1502-32.1667QC'd by NCIInactive0
Cytotoxic29.849380.614440Partial curve; high efficacy-4.52513.24750.7249-82.8026-2.1882-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.04879.32489.4674-17.343-9.0088-18.8502-4.8122-4.1352-5.0412-6.7317-5.864410.034619.8329-8.8964-20.6155-67.0487QC'd by LabotestCytotoxic29.849363.527240Partial curve; partial efficacy-4.52512.72020.9071-66.8238
Cytotoxic13.3332104.692182Complete curve; high efficacy-4.87513.51170.9601-100.33534.3568-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.17277.15452.81146.9308-0.1572-4.105825.3068-0.15731.08666.05980.85484.7774-0.6992-14.6485-90.6892-99.1727QC'd by NCICytotoxic16.7855114.729642Partial curve; high efficacy-4.77512.25260.9303-115.7849
Cytotoxic26.603293.069640Partial curve; high efficacy-4.57512.58840.7505-86.42426.6454-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.9291-25.457521.195211.0147-3.417213.682328.16354.114810.73649.90963.39471.32276.46260.2705-23.9356-68.9291QC'd by NCICytotoxic26.603283.904440Partial curve; high efficacy-4.57513.62720.9084-83.7035
Inactive0418.582530.92839.765411.01316.57590.04867.97495.3184.25971.95691.324516.866511.719816.94696.665118.5825QC'd by NCIInactive0
Cytotoxic10.590994.271582Complete curve; high efficacy-4.97512.72020.9664-98.4917-4.2203-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.2687-12.6266-9.71552.76191.16913.9341-2.1458-8.3456-7.78480.2987-4.4158-14.4266-11.7198-37.3785-91.2452-93.2687QC'd by NCICytotoxic10.590995.537682Complete curve; high efficacy-4.97512.40640.9837-98.3736
Inactive0421.512319.121525.006-1.94118.35391.0147-1.112212.94014.543614.711516.23313.403818.402626.76119.601221.5123QC'd by NCIInactive0
Inactive02.53340.618314.3567-5.901840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9449-6.97990.27957.2032-12.5846-2.9847-20.5724-7.1225-1.8195.056311.806413.728118.906723.71122.022-7.9449QC'd by NCICytotoxic33.491533.929720Single point of activity-4.47514.95490.5032-33.6955
Inactive0422.09676.01187.77648.964524.48872.336215.856811.60168.99512.18910.87535.056316.9556-9.06529.599522.0967QC'd by NCIInactive02.24810.359418.3831
Inactive04.95490.412622-0.482840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.1783-1.3463-1.5399-1.530212.584-0.6727.8822-4.87790.9615-0.7224-1.1373-9.9856-1.498-1.70110.588816.1783QC'd by ChembridgeInactive0
Cytotoxic29.849359.759320Single point of activity-4.52514.95490.7823-51.55738.202-30 0 0 0 0 1 0 0 0 0 0 0 0 0 0-45.047813.2325.4558-6.067513.70124.8368-25.68159.851213.6578.28768.3941-6.470517.960418.9919-1.1526-45.0478QC'd by NCICytotoxic33.491560.182320Single point of activity-4.47514.95490.9381-56.7139
Cytotoxic33.491577.960640Partial curve; high efficacy-4.47513.51170.6902-85.5053-7.5447-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.8614-23.92-6.4036-24.81696.0929-7.6795-2.09631.7283-20.9170.4558-10.7547-17.85467.586-12.7766-19.5831-67.8614QC'd by NCICytotoxic33.491567.176140Partial curve; high efficacy-4.47514.95490.7237-73.9128
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.10310.1406-0.03150.12620.060.1031QC'd by "NCI"0
Inactive040.02-0.0462-0.0096-0.0036-0.06880.02QC'd by "NCI"0
Inactive040.0352-0.02430.01330.08820.02270.0352QC'd by "NCI"0
Inactive04-0.0032-0.14120.03560.0067-0.0827-0.0032QC'd by "SigmaAldrich"0
Inactive04-0.0421-6.0E-4-0.01160.00418.0E-4-0.0421QC'd by "NCI"0
Inactive04-0.08870.05490.011900.0103-0.0887QC'd by "NCI"0
Inactive040.05490.14040.09660.0264-0.00150.0549QC'd by "NCI"0
Inactive04-0.0674-0.0024-0.1251-0.0771-0.0044-0.0674QC'd by "NCI"0
Inactive040.07660.11210.11820.1033-0.02320.0766QC'd by "NCI"0
Inactive040.02350.0289-0.01920.0237-0.01010.0235QC'd by "Labotest"0
Inactive04-1.0E-40.04880.0010.01740.0628-1.0E-4QC'd by "NCI"0
Inactive04-0.00820.10220.09650.07640.0317-0.0082QC'd by "NCI"0
Inactive040.04070.1229-0.00830.10480.07010.0407QC'd by "NCI"0
Inactive04-0.0682-0.10260.0427-0.0797-0.01-0.0682QC'd by "NCI"0
Inactive04-0.01790.0067-0.06430.0889-0.0161-0.0179QC'd by "NCI"0
Inactive04-0.0027-0.0933-0.0538-0.0212-0.0192-0.0027QC'd by "NCI"0
Inactive04-0.0156-0.0199-0.013-0.0358-0.0233-0.0156QC'd by "NCI"0
Inactive040.03220.01980.0576-0.00580.03020.0322QC'd by "Chembridge"0
Inactive040.10750.08580.07490.0633-0.01660.1075QC'd by "NCI"0
Inactive04-0.186-0.0569-0.018-0.0052-0.0633-0.186QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a [Homo sapiens]
External ID: AROA258
Protocol: Tox21 Assay Protocol Summary:

MCF-7 aro ERE cells were cultured in assay medium (Phenol red-free MEM containing 10% charcoal stripped FBS) two days prior to the assay. The cells were dispensed at 1,500 cells/4 uL/well into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of Testosterone (0.5 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 24 h. After the plates were incubated at 37C and 5% CO2 for 23.5 h, 1 uL of CellTiter-Fluor reagent (Promega, Madison, WI) of measuring cytotoxicity was added using a Bioraptr FRD workstation. The assay plates were incubated at 37C and 5% CO2 for additional 30 min and the fluorescence intensity was quantified by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo reagent (Promega) was added to each plate using a Bioraptr FRD and luminescence was quantified on a ViewLux (PerkinElmer) plate reader after 30 min incubation at room temperature.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002720541 uM-Replicate_1Activity at 0.0005955401 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.763 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 32.48 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-2.2066-1.1536-4.2174-8.711-6.6426-5.9488-2.0391-15.718-3.7027-4.5545-2.2801-3.7857-12.9599-13.1214-9.6886-2.2066QC'd by SigmaAldrichInactive00.60.524216
Inhibitor4.8311106.123784Complete curve; high efficacy-5.3163.92950.9965-109.1556-3.0318-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-111.611-2.2326-0.9982-2.1761-2.6217-1.2536-0.6776-10.6612-7.1504-2.5933-3.3688-27.6728-95.4648-108.5642-108.8003-111.611QC'd by SigmaAldrichInhibitor9.6393108.044283Complete curve; high efficacy-5.0162.33320.9737-111.3141
Inactive040.5035-0.5614-0.60061.8325-12.3047-7.0616-6.7801-7.5450.0745-7.0388-14.6296-17.129-10.3065-10.04952.84210.5035QC'd by SigmaAldrichInactive00.40.712212
Activator4.786735.1920Complete curve; partial efficacy-5.321.96730.788739.93654.74451.20 0 0 0 0 0 0 0 0 0 0 0 0 0 029.03948.85029.48829.65431.80068.671-15.61197.826913.14394.80715.616715.517731.452742.742446.782229.0394QC'd by SIGMAActivator6.026139.15410Partial curve; partial efficacy-5.220.90.716642.3193
Inactive0413.107-3.69333.8384-3.8759-2.794915.10135.67543.9491-0.481-0.0087-1.35722.7430.4844-0.2286-0.506613.107QC'd by SigmaAldrichInactive0
Inactive00.30.591126140 0 0 0 0 0 0 0 0 0 0 0 0 0 016.5070.22480.16584.54288.20863.07311.62359.30792.96323.47696.953417.436117.45098.245520.704216.507QC'd by SIGMAInactive0
Inactive00.50.6093342.518640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0871-0.04994.374311.83183.87946.24796.7535-0.81793.25538.241615.0466.393516.677312.040126.46280.0871QC'd by SIGMAInactive0
Inactive049.877725.13764.246517.21280.730714.42964.63272.88386.0378.01461.82367.76-0.9897-0.539911.31369.8777QC'd by SIGMAInactive0
Inactive03.1320.3295-2.85236.540 0 0 0 0 0 0 0 0 0 0 0 0 0 114.23829.08182.781819.61592.0565.20476.73762.60575.76535.52163.30952.0753-14.0436-1.25855.163414.2382QC'd by SIGMAInactive00.90.596219
Inactive04-8.817950.49373.29484.0553-0.6701-0.6623-1.2923-7.08623.7302-10.61697.0748-9.6132-5.8222-0.2724-6.1574-8.8179QC'd by SIGMAInactive02.40640.4689-16.5545
Inactive048.37919.77034.99511.86981.2146-1.77476.29237.9265.26814.22540.00622.72662.48328.463714.10848.3791QC'd by SIGMAInactive00.60.514216
Inactive04-8.27240.0281-1.4766-2.28621.25773.831-0.44142.53031.7269-0.7283-1.5332-1.491-14.22041.08090.4188-8.2724QC'd by SigmaAldrichInactive0
Inactive04.95490.3969-6.05574.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.12147.3682.91070.72930.8159.56672.9381-11.3075-8.80042.3752.7959-1.0346-18.7964-0.6442-13.2151-0.1214QC'd by SigmaAldrichInactive0
Inactive041.44823.58520.4997-0.7201-9.4521-0.6989-1.3229-8.92980.74661.0939-11.5869-1.93430.8104-13.6039-1.16031.4482QC'd by SIGMAInactive02.33320.623112.5
Inhibitor60.261387.346841Partial curve; high efficacy-4.223.19250.9468-91.7081-4.3613-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.2637-0.7151-1.4324-8.64940.3488-1.0106-0.8286-10.6048-2.9472-0.5851-2.1641-10.2189-13.2296-5.2897-23.1809-73.2637QC'd by SigmaAldrichInhibitor53.707981.468141Partial curve; high efficacy-4.273.92950.9434-84.2519
Inactive04.95490.5801-7.1836-0.829740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.1223-1.2322-1.1081-1.7584-8.8414-5.325-10.4209-6.1753-4.2522-4.2314-10.9863-7.5165-5.1054-7.8585-8.4654-9.1223QC'd by ChemServiceInactive04.95490.35784.5
Inhibitor24.3613103.983841Partial curve; high efficacy-4.61332.35310.9238-97.82326.1605-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.92071.595-3.3685-2.9295-0.3657-0.674810.0521.01462.20929.916924.275426.29-4.4212-30.9132-70.0689-96.9207QC'd by SIGMAInhibitor27.3338108.053740Partial curve; high efficacy-4.56331.98870.9107-103.8107
Inactive04-1.8107-0.19851.1239-2.7571-9.5761-2.0759-8.4016-9.53090.2125-1.6114-8.3569-1.504-7.968-1.193-6.8529-1.8107QC'd by SigmaAldrichActivator42.969237.94450Partial curve; partial efficacy-4.36682.72020.911335.5
Inactive04-0.8051-6.3306-0.3852-7.0596-0.1656-3.4084-6.7899-11.8797-7.7193-10.2069-7.5291-14.8365-8.1408-1.5169-2.1071-0.8051QC'd by SigmaAldrichActivator0.436315.75320Complete curve; partial efficacy; poor fit-6.36024.95490.518712.5053
Inactive04-0.53480.5678-2.8997-2.84370.38943.491-6.100814.436-0.80381.870613.74841.2268-0.08231.5329-0.0037-0.5348QC'd by SigmaAldrichInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.06820.17150.15520.2805-0.08310.0682QC'd by "APAC"0
Inactive040.0073-0.03930.005-0.09740.03070.0073QC'd by "APAC"0
Inactive04-0.4123-0.248-0.1541-0.1037-0.0973-0.4123QC'd by "APAC"0
Inactive040.19330.41050.28830.44640.38910.1933QC'd by "APAC"0
Inactive040.44160.65360.7260.63220.73960.4416QC'd by "APAC"0
Inactive040.2127-0.00470.08240.2587-0.01090.2127QC'd by "APAC"0
Inactive040.13480.40170.15030.02750.21030.1348QC'd by "APAC"0
Inactive040.16380.07840.19640.35280.10370.1638QC'd by "APAC"0
Inactive04-0.0775-0.1328-0.144-0.2205-0.105-0.0775QC'd by "APAC"0
Inactive040.12810.06390.0321-0.01010.04060.1281QC'd by "APAC"0
Inactive04-0.4235-0.3306-0.3534-0.2876-0.4525-0.4235QC'd by "APAC"0
Inactive040.1880.24950.21320.11330.30530.188QC'd by "APAC"0
Inactive040.26490.13370.33710.1823-0.01240.2649QC'd by "APAC"0
Inactive040.14720.44310.35470.41120.45620.1472QC'd by "APAC"0
Inactive040.18370.1140.0230.16450.38450.1837QC'd by "APAC"0
Inactive04-0.5082-0.4883-0.5711-0.5038-0.4992-0.5082QC'd by "APAC"0
Inactive04-0.2494-0.1585-0.0187-0.265-0.2494-0.2494QC'd by "APAC"0
Inactive04-0.489-0.6545-0.2063-0.2875-0.5573-0.489QC'd by "APAC"0
Inactive04-0.1512-0.1725-0.2697-0.1595-0.2932-0.1512QC'd by "APAC"0
Inactive040.1730.29550.30070.26150.34070.173QC'd by "APAC"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53
External ID: P53823
Protocol: Please refer to other AIDs, 651631 and 651633, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the P53 assay (AID 651631) and cell viability counter screen (AID 651633). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0inconclusive agonist15.55089081inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusive agonistinconclusive agonist18.58791134inactive0active agonist29.8492948138.73741641inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusiveactive agonist28.7254875625.5057883active antagonist29.84929481-51.18360188inactive0active antagonist29.84929481-98.84256078SigmaAldrich
inconclusiveinconclusive agonist14.35525499inconclusive antagonist31.61797672-26.09239449inactive0active antagonist26.603212-72.63099375NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inconclusive antagonistLabotest
inconclusiveactive agonist33.4914596364.83524463active antagonist33.49145963-59.84708639inactive0inconclusive antagonist28.17955142-95.15844265NCI
inconclusive agonistinconclusive agonist10.75907896inactive0active agonist19.07705083inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusiveinconclusive agonist33.4914596379.63843875inconclusive antagonist31.61797672-53.76954664inactive0active antagonist29.84929481-106.2599059NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0Chembridge
inactiveinactive0inactive0inactive0inactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0303-0.04260.0285-0.09190.0085-0.0303QC'd by "NCI"0
Inactive040.0853-0.06580.02019.0E-40.06280.0853QC'd by "NCI"0
Inactive040.16730.04180.01560.0204-0.00980.1673QC'd by "NCI"0
Inactive04-0.1980.02190.0160.02350.0689-0.198QC'd by "SigmaAldrich"0
Inactive040.0038-0.0014-0.00825.0E-4-0.1170.0038QC'd by "NCI"0
Inactive040.0026-0.0041-0.01760.0697-0.01480.0026QC'd by "NCI"0
Inactive040.1333-0.0845-0.0206-0.01310.12030.1333QC'd by "NCI"0
Inactive040.03690.00440.0618-0.01070.01570.0369QC'd by "NCI"0
Inactive04-0.02150.02550.01530.1030.0492-0.0215QC'd by "NCI"0
Inactive04-0.00280.08780.0034-0.01623.0E-4-0.0028QC'd by "Labotest"0
Inactive040.02210.0083-0.0285-0.04060.10790.0221QC'd by "NCI"0
Inactive040.02430.10020.08470.0514-0.00220.0243QC'd by "NCI"0
Inactive040.00680.024-0.00130.0328-0.11050.0068QC'd by "NCI"0
Inactive040.03090.0251-0.2255-0.1044-0.07930.0309QC'd by "NCI"0
Inactive04-0.0428-0.0779-0.07410.0110.0229-0.0428QC'd by "NCI"0
Inactive040.07660.0357-0.02130.0861-0.01260.0766QC'd by "NCI"0
Inactive04-0.0349-0.0548-0.0746-0.0452-0.1742-0.0349QC'd by "NCI"0
Inactive040.15650.01040.0178-0.0320.02410.1565QC'd by "Chembridge"0
Inactive04-0.05070.0691-0.01840.01950.0897-0.0507QC'd by "NCI"0
Inactive04-0.0232-0.1816-0.1161-0.2126-0.2187-0.0232QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.060.0769-0.0561-0.05340.0765-0.06QC'd by "NCI"0
Inactive04-0.02860.01850.15430.03970.0134-0.0286QC'd by "NCI"0
Inactive041.25510.11730.01450.07070.51551.2551QC'd by "NCI"0
Inactive040.0380.0229-0.1395-0.01880.42040.038QC'd by "SigmaAldrich"0
Inactive041.3250.07660.1836-0.10240.07711.325QC'd by "NCI"0
Inactive040.1088-0.12430.0941-0.0246-0.04550.1088QC'd by "NCI"0
Inactive040.00260.0529-0.1116-0.1678-0.11720.0026QC'd by "NCI"0
Inactive040.17340.0511-0.06420.11-0.13760.1734QC'd by "NCI"0
Inactive040.0031-0.0257-0.0731-0.021-0.01490.0031QC'd by "NCI"0
Inactive04.0950.98722.5040 0 0 0 02.51080.00570.26280.01340.77542.5108QC'd by "Labotest"0
Inactive04-0.05950.0115-0.03130.04540.0652-0.0595QC'd by "NCI"0
Inactive040.7551-0.0030.0690.14220.06940.7551QC'd by "NCI"0
Inactive04-0.0762-0.099-0.14750.0756-0.1338-0.0762QC'd by "NCI"0
Inactive040.0533-0.1182-0.00850.0808-0.08810.0533QC'd by "NCI"0
Inactive041.4117-0.0519-0.0295-0.05670.23241.4117QC'd by "NCI"0
Inactive040.15250.02280.10290.03280.11910.1525QC'd by "NCI"0
Inactive040.97520.1286-0.0289-0.0041-0.01590.9752QC'd by "NCI"0
Inactive040.090.11160.0522-0.0224-0.17680.09QC'd by "Chembridge"0
Inactive040.12760.09120.04220.0790.08710.1276QC'd by "NCI"0
Inactive04-0.05040.00170.0374-0.2014-0.0226-0.0504QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0468-1.0E-4-0.0634-0.0128-0.1309-0.0468QC'd by "NCI"0
Inactive04-0.02170.0466-0.04120.00330.0551-0.0217QC'd by "NCI"0
Inactive04-0.0248-0.00450.0622-0.03730.0284-0.0248QC'd by "NCI"0
Inactive040.01860.0540.055-7.0E-40.08120.0186QC'd by "SigmaAldrich"0
Inactive040.02420.07270.1578-0.01480.02860.0242QC'd by "NCI"0
Inactive040.08870.03620.13790.04160.03120.0887QC'd by "NCI"0
Inactive040.10310.0424-0.0028-0.06470.0120.1031QC'd by "NCI"0
Inactive040.022-0.01990.0104-0.01420.03070.022QC'd by "NCI"0
Inactive040.58190.1190.05910.03290.05860.5819QC'd by "NCI"0
Inactive04-0.01230.04580.0457-0.03880.0399-0.0123QC'd by "Labotest"0
Inactive04-0.0094-0.02560.0289-0.00760-0.0094QC'd by "NCI"0
Inactive040.11950.07450.00670.004-0.05970.1195QC'd by "NCI"0
Inactive04-0.0059-0.05640.01470.0049-0.0156-0.0059QC'd by "NCI"0
Inactive04-0.05470.0295-0.0247-0.0665-0.0356-0.0547QC'd by "NCI"0
Inactive04-0.0413-0.0059-0.1195-0.0027-0.0175-0.0413QC'd by "NCI"0
Inactive040.175-0.00450.11290.06590.06270.175QC'd by "NCI"0
Inactive04-0.0317-0.0316-0.01050.0141-0.0074-0.0317QC'd by "NCI"0
Inactive040.06210.0243-0.0520.16910.01120.0621QC'd by "Chembridge"0
Inactive040.0158-0.02480.0493-0.0242-0.02880.0158QC'd by "NCI"0
Inactive04-0.0654-0.1331-0.0734-0.03930.0109-0.0654QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.2003-0.01150.00710.23730.09540.2003QC'd by "NCI"0
Inactive040.1113-0.03910.08984.0E-4-0.03890.1113QC'd by "NCI"0
Inactive04-0.09730.0277-0.0084-0.00980.0055-0.0973QC'd by "NCI"0
Inactive04-0.1827-0.0289-0.0224-0.1537-0.0181-0.1827QC'd by "SigmaAldrich"0
Inactive040.5452-0.03350.0032-0.01370.01630.5452QC'd by "NCI"0
Inactive04-0.05130.011-0.0106-0.0503-0.0065-0.0513QC'd by "NCI"0
Inactive04-0.0252-0.1196-0.0502-0.05650.0376-0.0252QC'd by "NCI"0
Inactive040.10450.0373-0.01590.03940.00210.1045QC'd by "NCI"0
Inactive04-0.24220.0063-0.0071-0.0119-0.0133-0.2422QC'd by "NCI"0
Inactive04.50450.98673040 0 0 0 03.1340.15520.13580.19860.6053.134QC'd by "Labotest"0
Inactive04-0.0090.01850.03930.2310.0436-0.009QC'd by "NCI"0
Inactive040.07510.02710.22620.17550.01740.0751QC'd by "NCI"0
Inactive040.0132-0.0598-0.0350.09430.07230.0132QC'd by "NCI"0
Inactive049.0E-4-0.0911-0.05740.15930.17099.0E-4QC'd by "NCI"0
Inactive040.6834-0.1194-0.00280.3720.19860.6834QC'd by "NCI"0
Inactive040.1104-0.08290.06180.16230.0230.1104QC'd by "NCI"0
Inactive040.5456-0.0786-0.0186-0.0058-0.00230.5456QC'd by "NCI"0
Inactive04-0.1424-0.0976-0.10020.027-0.1146-0.1424QC'd by "Chembridge"0
Inactive040.0252-0.0593-0.08240.12910.04990.0252QC'd by "NCI"0
Inactive040.0384-0.2038-0.1551-0.007-0.01920.0384QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.12420.2628-0.1782-0.4447-0.2156-0.1242QC'd by "NCI"0
Inactive040.52820.2696-0.353-0.2319-0.17610.5282QC'd by "NCI"0
Inactive040.36990.109-0.00360.2172-0.0050.3699QC'd by "NCI"0
Inactive040.003-0.1398-0.2166-0.05930.03410.003QC'd by "SigmaAldrich"0
Inactive040.0037-0.18840.15210.18170.12320.0037QC'd by "NCI"0
Inactive040.42260.0606-0.0267-0.1598-0.03750.4226QC'd by "NCI"0
Inactive04-0.1083-0.0289-0.054-0.2945-0.072-0.1083QC'd by "NCI"0
Inactive04-0.0618-0.03660.04-0.2576-0.1156-0.0618QC'd by "NCI"0
Inactive040.0450.2884-0.027-0.166-0.30740.045QC'd by "NCI"0
Inactive04-0.2251-0.37-0.4364-0.0983-0.1209-0.2251QC'd by "Labotest"0
Inactive04-0.32420.23140.0134-0.2318-0.0596-0.3242QC'd by "NCI"0
Inactive04-0.01610.01530.03390.01490.0696-0.0161QC'd by "NCI"0
Inactive04-0.00830.0949-0.2516-0.1363-0.3201-0.0083QC'd by "NCI"0
Inactive040.1281-0.3790.11360.0866-0.02890.1281QC'd by "NCI"0
Inactive04-0.0989-0.0902-0.1041-0.2289-0.1987-0.0989QC'd by "NCI"0
Inactive040.0739-0.0110.01860.02430.02880.0739QC'd by "NCI"0
Inactive04-0.20280.08760.015-0.0122-0.012-0.2028QC'd by "NCI"0
Inactive04-0.152-0.0722-0.03940.08260.0334-0.152QC'd by "Chembridge"0
Inactive04-0.0720.1489-0.00810.015-0.0036-0.072QC'd by "NCI"0
Inactive04-0.1159-0.19220.11950.16620.2987-0.1159QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1115-0.1251-0.0765-0.06640.0949-0.1115QC'd by "SIGMA"0
Inactive04-0.0069-0.10850.02610.0208-0.0462-0.0069QC'd by "SigmaAldrich"0
Inactive04-0.172-0.0309-0.0124-0.0718-0.0262-0.172QC'd by "SIGMA"0
Inactive040.0130.0073-0.01730.01340.00240.013QC'd by "SigmaAldrich"0
Inactive04-0.052-0.0612-0.0736-0.0496-0.0413-0.052QC'd by "SigmaAldrich"0
Inactive04-0.0569-0.01650.10050.1139-0.0959-0.0569QC'd by "SigmaAldrich"0
Inactive04-0.0353-0.0623-0.04670.00960.0134-0.0353QC'd by "SIGMA"0
Inactive040.22820.00980.01520.0163-0.02330.2282QC'd by "Alfa Aesar"0
Inactive04-0.1287-0.0353-0.0866-0.012-0.0014-0.1287QC'd by "SIGMA"0
Inactive04-0.0565-0.1141-0.0255-0.009-0.0415-0.0565QC'd by "SIGMA"Inactive04
Inactive04-0.1244-0.1158-0.0769-0.0272-0.0887-0.1244QC'd by "SIGMA"0
Inactive04-0.1459-0.077-0.0696-0.0992-0.1072-0.1459QC'd by "SIGMA"0
Inactive04-0.0112-0.12120.0729-0.0657-0.1082-0.0112QC'd by "SIGMA"0
Inactive04-0.0758-0.1319-0.0931-0.0564-0.0431-0.0758QC'd by "SIGMA"0
Inactive04-0.0061-0.0301-0.0049-0.0052-0.0205-0.0061QC'd by "SigmaAldrich"0
Inactive040.06630.0020.1992-0.0417-0.05850.0663QC'd by "SigmaAldrich"0
Inactive040.1620.0128-0.0595-0.0493-0.05030.162QC'd by "Interchem"0
Inactive04-0.0217-0.0781-0.08430.00810.004-0.0217QC'd by "SigmaAldrich"0
Inactive040-0.0307-1.0E-4-0.0089-0.03580QC'd by "SigmaAldrich"0
Inactive04-0.02990.0039-0.03650.0192-0.0786-0.0299QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: AROV112
Protocol: Tox21 Assay Protocol Summary:

MCF-7 aro ERE cells were cultured in assay medium (Phenol red-free MEM containing 10% charcoal stripped FBS) two days prior to the assay. The cells were dispensed at 1,500 cells/4 uL/well into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of Testosterone (0.5 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 24 h. After the plates were incubated at 37C and 5% CO2 for 23.5 h, 1 uL of CellTiter-Fluor reagent (Promega, Madison, WI) of measuring cytotoxicity was added using a Bioraptr FRD workstation. The assay plates were incubated at 37C and 5% CO2 for additional 30 min and the fluorescence intensity was quantified by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002720541 uM-Replicate_1Activity at 0.0005955401 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00613 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.342 uM-Replicate_1Activity at 0.763 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 32.48 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0413.0889-1.66864.478718.6854-0.48264.7953-0.59428.07730.92478.9629-2.196715.345715.139216.4786.722113.0889QC'd by NCIInactive0
Cytotoxic13.333236.732221Complete curve; partial efficacy-4.87514.95490.7923-29.6627.0702-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14381.479820.25985.08754.60124.75079.9862-3.20264.47916.0258-0.530311.199220.09346.1387-29.52-31.1438QC'd by NCICytotoxic21.1317103.350741Partial curve; high efficacy-4.67511.86170.9757-102.1811
Inactive040.4471-2.8001-1.7403-1.12262.98012.11316.665210.218212.80795.8803-0.2215-10.6114-1.02321.931912.73780.4471QC'd by NCIInactive0
Cytotoxic29.849391.037120Single point of activity-4.52514.95490.971-90.40840.6287-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.49860.17360.6935-1.3312-0.206112.2146-4.40990.0668-1.3756-0.3616-1.11661.2081-0.25880.0225-8.4892-81.4986QC'd by SigmaAldrichCytotoxic29.849396.057440Partial curve; high efficacy-4.52514.0950.9745-98.4887
Cytotoxic29.849343.259620Partial curve; partial efficacy; poor fit-4.52512.58840.654-43.934-0.6743-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.54971.51315.83030.6388-4.89485.5838-6.034-5.42513.19371.27950.2248-7.0642-13.9432-0.3387-11.983-33.5497QC'd by NCICytotoxic23.710154.80320Partial curve; partial efficacy-4.62513.06540.9118-56.0531
Inactive03.990.463312-3.545940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.1224-1.1431-0.4077-9.2962-6.7439-1.3041-5.108-0.428-0.48521.6732-2.7718-12.1216-1.7511-0.57919.852-5.1224QC'd by NCIInactive0
Inactive048.2451-2.30262.27657.3956-4.68135.92238.448911.15386.86045.9576.8113.9931-7.5923-6.506313.20258.2451QC'd by NCIInactive0
Inactive047.8779-11.401-0.64871.58362.34767.156-6.7357-11.41271.6491-7.1693-11.7901-8.769-6.8463-0.06161.77097.8779QC'd by NCIInactive04.95490.57718
Cytotoxic29.849357.823420Single point of activity-4.52514.95490.8931-57.47810.3453-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.2317-1.15572.6188-7.7075-0.359.48620.1230.66930.6672-2.0531-1.7983-5.341910.3150.1178-7.6014-51.2317QC'd by NCICytotoxic26.603247.886120Partial curve; partial efficacy-4.57513.1320.946-50.222
Inactive04-2.258415.0081.8981-5.02357.271710.479510.62950.407-2.5232-2.4835-0.74710.0879-1.3303-2.762810.6838-2.2584QC'd by LabotestInactive0
Inactive04.44950.4193-2.29222.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.9246-0.8801-0.53812.6488-0.05617.27753.7735.28930.09192.13935.6234-1.8779-4.8269-1.53031.2059-3.9246QC'd by NCIInactive03.92950.6224-26.8855
Inactive044.84140.39352.1814-15.55856.1583-2.7506-1.29682.408-3.1984-19.027510.67640.856914.6462-2.9317-22.00254.8414QC'd by NCIInactive0
Inactive04-3.117-2.9332-1.54190.48350.1637-4.1579-1.392-1.1741-1.09652.2022-5.70182.53112.8257-1.2786-0.6983-3.117QC'd by NCIInactive0
Cytotoxic29.849370.737440Partial curve; high efficacy-4.52514.95490.9648-74.0453-3.3079-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-66.7044-0.8515-0.6476-6.75680.34160.33811.3744-2.6166-7.5972-0.9959-6.0997-2.5425-6.0215-8.4358-12.6041-66.7044QC'd by NCICytotoxic29.849394.666240Partial curve; high efficacy-4.52514.95490.9892-97.0028
Inactive01.10.33837-5.697440 0 0 0 0 0 0 0 0 0 0 0 0 0 07.3431-6.3907-4.9726-7.29748.7208-13.9145-5.2667-5.7344-12.4941-5.56985.73531.1859-7.230414.63531.82357.3431QC'd by NCIInactive00.90.589217
Inactive045.737312.5288-1.0974-2.79388.27274.0907-1.41678.99574.80517.5768-1.30747.23573.08392.88293.96365.7373QC'd by NCIInactive03.19250.4553-4.6844
Inactive044.5023.9295-8.0465-3.62329.46645.37291.138612.185-3.65222.981114.46385.46410.06047.6392-5.06044.502QC'd by NCIInactive0
Inactive04-1.9982-3.6344-4.6559-0.3788-2.1166-1.2585-1.98810.0232-0.9085-1.1425-5.0225-1.24591.0659-5.4568-3.298-1.9982QC'd by ChembridgeInconclusive26.603228.322310Partial curve; partial efficacy; poor fit-4.57512.09370.871525.5
Inactive04-16.5603-2.74410.3192.3141-0.1723-19.45910.0669-17.7681-2.4009-3.26419.5003-3.13731.90082.00541.7817-16.5603QC'd by NCICytotoxic33.491536.815220Partial curve; partial efficacy; poor fit-4.47514.95490.7907-33.8152
Inactive04-9.10111.67360.31128.9066.348410.2071-6.926413.5429-4.395717.17929.543-14.114110.7621-0.2142-14.2769-9.1011QC'd by NCIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.77120.05930.0635-0.0984-0.218-0.7712QC'd by "Prestwick Chemical; Inc."0
Inactive040.28480.45950.13770.23990.45920.2848QC'd by "Prestwick Chemical; Inc."0
Inactive040.10910.08720.002-0.128-0.01040.1091QC'd by "Prestwick Chemical; Inc."0
Inactive040.35690.44360.30790.14920.38140.3569QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4718-0.21590.1141-0.2538-0.4782-0.4718QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.7519-0.0052-0.0382-0.3499-0.5531-0.7519QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3026-0.176-0.2919-0.2217-0.1667-0.3026QC'd by "Prestwick Chemical; Inc."0
Inactive040.00260.10340.01420.20370.21520.0026QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.309-0.54610.3903-0.3625-0.0293-0.309QC'd by "Prestwick Chemical; Inc."0
Inactive040.1015-0.23980.08980.41030.37930.1015QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.02650.19180.1501-0.07350.0724-0.0265QC'd by "Prestwick Chemical; Inc."0
Inactive040.3519-0.54170.1370.20740.37870.3519QC'd by "Prestwick Chemical; Inc."0
Inactive040.11140.07490.32080.3560.48040.1114QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.45320.0227-0.0204-0.4367-0.3391-0.4532QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4937-0.7632-0.0181-0.4913-0.1598-0.4937QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.2868-0.3361-0.3349-0.465-0.3474-0.2868QC'd by "Prestwick Chemical; Inc."0
Inactive040.33880.03910.14580.56180.08170.3388QC'd by "Prestwick Chemical; Inc."0
Inactive040.5747-0.55850.02420.36260.57350.5747QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3048-0.2054-0.3202-0.3697-0.1434-0.3048QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.27210.25420.1392-0.3556-0.4304-0.2721QC'd by "Prestwick Chemical; Inc."0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0029-0.0082-0.00260.13990.0699-0.0029QC'd by "SIGMA"0
Inactive04-0.10090.004-0.1385-0.05520.0167-0.1009QC'd by "ChromaDex"0
Inactive04-0.00270.04690.0106-0.0323-0.0264-0.0027QC'd by "SIGMA"0
Inactive040.0680.04520.00930.1349-0.05650.068QC'd by "SigmaAldrich"0
Inactive04-0.01020.00830.0497-0.0368-0.1188-0.0102QC'd by "Sensient"0
Inactive040.16110.01260.0217-0.06560.10580.1611QC'd by "Pfaltz-Bauer"0
Inactive040.01860.00820.0242-0.11250.1760.0186QC'd by "SigmaAldrich"0
Inactive040.0141-0.0188-0.03030.00210.09840.0141QC'd by "SigmaAldrich"0
Inactive04-0.06960.0137-0.0094-0.0575-0.0122-0.0696QC'd by "SigmaAldrich"0
Inactive04-0.0879-0.00670.1326-0.0156-0.0041-0.0879QC'd by "SigmaAldrich"0
Inactive040.0162-0.0159-0.0079-0.01810.08710.0162QC'd by "SigmaAldrich"0
Inactive040.02930.0807-0.0391-0.1788-0.09160.0293QC'd by "SIGMA"0
Inactive04-0.0528-0.0224-0.08430.0049-0.0082-0.0528QC'd by "SIGMA"0
Inactive040.11520.05240.1778-0.0592-0.05560.1152QC'd by "SIGMA"0
Inactive04-0.03240.04210.01430.01780.0302-0.0324QC'd by "SIGMA"0
Inactive04-0.1527-0.0095-0.1287-0.0855-0.0912-0.1527QC'd by "SIGMA"0
Inactive040.1560.0209-0.00190.010.00660.156QC'd by "SIGMA"0
Inactive040.0052-0.00170.0141-0.07196.0E-40.0052QC'd by "SIGMA"0
Inactive04-0.0288-0.0779-0.0066-0.0587-0.0039-0.0288QC'd by "SIGMA"0
Inactive04-0.0014-0.08470.0444-0.017-0.0041-0.0014QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0993-0.0315-0.0456-0.0314-0.0445-0.0993QC'd by "SIGMA"0
Inactive04-0.0413-0.330.9732-0.1408-0.2626-0.0413QC'd by "SIGMA"0
Inactive043.0E-4-0.0951-0.0908-0.0608-0.01023.0E-4QC'd by "SIGMA"0
Inactive040.00362.0E-4-0.1154-0.1852-0.02580.0036QC'd by "SIGMA"0
Inactive04-0.08410.02920.0072-0.0606-0.0747-0.0841QC'd by "SIGMA"0
Inactive04-0.0562-0.02190.0027-0.0792-0.1435-0.0562QC'd by "SIGMA"0
Inactive04-0.0228-0.2225-0.17238.0E-4-0.2899-0.0228QC'd by "SIGMA"0
Inactive04-0.10910.0012-0.0968-0.007-0.2223-0.1091QC'd by "SIGMA"0
Inactive04-0.03890.07040.0162-0.0035-0.0387-0.0389QC'd by "SIGMA"0
Inactive040.0777-0.1888-0.0421-0.0179-0.13070.0777QC'd by "SIGMA"0
Inactive04-0.1076-0.1771-0.0039-0.04160.0041-0.1076QC'd by "SIGMA"0
Inactive04-0.0441-0.05340.0039-0.0433-0.1015-0.0441QC'd by "TCI"0
Inactive04-0.42250.18470.0082-0.0822-0.0703-0.4225QC'd by "SIGMA"0
Inactive040.0630.0914-0.00420.0899-0.04430.063QC'd by "SIGMA"0
Inactive040.21370.17290.0260.23310.10530.2137QC'd by "SIGMA"0
Inactive04-0.0274-0.01920.12090.04090.0156-0.0274QC'd by "SIGMA"0
Inactive040.0634-0.01480.0720.08030.08560.0634QC'd by "SIGMA"0
Inactive040.0335-0.04990.1012-0.00170.26310.0335QC'd by "SIGMA"0
Inactive04-0.0334-0.0211-0.0049-0.03310.19-0.0334QC'd by "SIGMA"0
Inactive040.15920.01470.11910.10190.12680.1592QC'd by "SIGMA"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1742-0.0105-0.0707-0.708-0.8608-0.1742QC'd by "NCI"0
Inactive04-0.15950.087-0.0389-0.0424-0.0089-0.1595QC'd by "NCI"0
Inactive040.17150.56230.2590.06620.03240.1715QC'd by "NCI"0
Inactive040.04060.1038-4.0E-40.08940.12640.0406QC'd by "SigmaAldrich"0
Inactive040.439-0.1165-0.2370.53740.0650.439QC'd by "NCI"0
Inactive04-0.1787-0.0681-0.0763-0.05880.0674-0.1787QC'd by "NCI"0
Inactive04-0.26880.03020.2349-0.1201-0.1287-0.2688QC'd by "NCI"0
Inactive04-0.1086-0.2195-0.0573-0.14660.1358-0.1086QC'd by "NCI"0
Inactive04-0.1833-0.03-0.0379-0.4701-0.1431-0.1833QC'd by "NCI"0
Inactive04-0.9523-1.1611-0.9118-1.0013-1.0781-0.9523QC'd by "Labotest"0
Inactive04-0.2307-0.10680.4032-0.0433-0.0679-0.2307QC'd by "NCI"0
Inactive040.06170.30390.1775-0.00510.08570.0617QC'd by "NCI"0
Inactive04-0.1350.1614-0.083-0.1721-0.0432-0.135QC'd by "NCI"0
Inactive040.2214-0.6929-0.11650.0685-0.05560.2214QC'd by "NCI"0
Inactive04-0.2027-0.05290.0564-0.9701-0.3154-0.2027QC'd by "NCI"0
Inactive040.06990.0444-0.03810.03760.19960.0699QC'd by "NCI"0
Inactive040.0459-0.04550.12930.11980.02850.0459QC'd by "NCI"0
Inactive04-0.0306-0.0309-0.01430.02940.0175-0.0306QC'd by "Chembridge"0
Inactive04-0.02680.23620.2368-0.0791-0.0097-0.0268QC'd by "NCI"0
Inactive040.0114-0.9843-0.7454-0.13590.21030.0114QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRA481
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/6 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514703 uM-Replicate_1W460-Activity at 0.0001157795 uM-Replicate_1W460-Activity at 0.0002347639 uM-Replicate_1W460-Activity at 0.0005064679 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.18 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.15 uM-Replicate_1W460-Activity at 213.3 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive040.7562-2.0191-2.8763-0.9026-3.551-0.7809-0.2770.3016-2.05597.6695-0.4571-0.4785-0.3067-3.19312.29950.7562102.72020.5091-13.21010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8015
Inconclusive2.683243.355504.95490.33697-1.259840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.13651.0101-0.5652-4.3951-0.2458-3.9615-0.72250.0703-5.2165-4.71332.5855-0.82580.39810.8412-1.08125.1365103.06540.430911-0.15540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4779
Inactive00.9310.515-2.2498140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.19170.0432-0.94582.66191.9187-0.00912.6540.7197-0.8071-0.0436-0.1456-2.86940.2333-3.1248-1.627-2.19171040.5349
Cytotoxic23.914564.59580Partial curve; partial efficacy-4.72133.1320.9596-43.45790.2745-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.3622.89331.82591.0907-0.1463-0.10590.92180.09150.19131.3078-6.7647-0.7119-0.62320.4675-17.992-39.362100.30.5041-9.1529140 0 0 0 0 0 0 0 0 0 0 0 0 0 13.6116
Inactive00.50.455-21.31571.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.42971.0157-1.7522.7232.69846.869-3.71430.19816.1321-2.0281-8.9254-4.3551-0.3757-5.1288-2.2826-14.4297100.20.470911.5-5.046140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.922
Inconclusive15.08948.866903.51170.44866.5-1.011940 0 0 0 0 0 0 0 0 0 0 0 0 0 05.50351.07060.905-0.25830.69930.4392-0.1511-3.58922.2605-4.5752-0.49010.3402-2.2626-5.42666.35045.5035103.1320.5006-12.72791.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.019
Activator0.095244.78110Single point of activity-7.02134.95490.971588.6934-1.347630 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.2744-4.73250.61890.21280.81980.5686-0.35281.205386.9543-3.9984-3.1116-0.3361-4.4875-4.0498-7.4011-0.27440Single point of activity-7.02134.95490.969543.878-0.903130 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.1232
Inactive043.93180.3895-0.21130.182-0.9258-0.4412-3.95122.1721-0.1688-5.0997-0.15442.3995-4.165-0.19191.89093.9318104-1.6204
Inactive04.95490.4549-2.1971140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.39480.2258-0.38513.3271.6718-0.0652.57751.6671-0.09210.011-0.24882.0368-2.0108-3.4976-0.2290.3948103.51170.49812-0.310640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5444
Inactive04.95490.49990.779540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.19890.56481.7838-0.99043.56074.2105-1.85041.559-0.7889-0.57311.13450.3821.1458-0.6344-0.05567.19891043.2539
Inconclusive26.832542.156903.1320.6237-18.228140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.8509-0.43261.3737-0.723-1.5954-0.98793.3248-0.25092.6333-1.3551-3.191.65445.081210.7255-16.44-14.85090Complete curve; partial efficacy; poor fit-5.32134.95490.903616-1.39761.40 0 0 0 0 0 0 0 0 0 0 0 0 1 014.2731
Inactive01.3310.44069-1.315540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.7682-8.1796-1.2864-0.92690.0489-1.1023.6629-5.3855-2.0892-3.4173.63520.2376-0.11450.36824.02527.7682104.0950.645512.50.056140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.4789
Inactive04-1.77665.9446-8.071110.9483-0.66150.7628-0.19420.81740.424-0.04970.3107-1.4675-4.3278-0.9634-3.4067-1.77661040.3915
Cytotoxic30.106580.09980Single point of activity-4.57134.95490.9233-34.1878-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.15651.4442-1.42590.5602-0.5727-1.5149-1.1531-1.7711-0.5991-1.6507-0.5856-0.7334-2.4262-6.8854-0.1814-30.15650Single point of activity-4.57134.95490.964133.76670.413730 0 0 0 0 0 0 0 0 0 0 0 0 0 0123.858
Inactive04.0950.6978-0.5-7.11540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.8355-7.1792-4.2685-1.14751.1488-2.8672-0.65330.9563-0.5809-0.63290.28570.6351.0765-3.2022-0.934-0.8355104.95490.8946-0.469515.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4115
Inactive047.6683-0.213812.7411-0.95732.68175.82062.76031.9502-1.1272.6603-0.154-4.84897.2899-0.02820.21517.6683100.70.4452-6.3234340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.9779
Inactive04.95490.38580-3.382540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3426-2.7245-4.1769-2.5201-5.3186-0.55251.2952-5.152-6.9854-0.68020.87571.22690.5227-3.0321.11160.3426104-1.3858
Inactive043.5373-0.4222-4.6002-0.5607-0.0671-0.45211.69491.7648-0.6170.1086-4.2139-4.41190.48912.0611-0.44833.5373104-0.2942
Activator10.682283.89470Single point of activity-4.97133.92950.884675.0549-2.701730 0 0 0 0 0 0 0 0 0 0 0 0 0 10.7587-0.7027-0.0356-2.9874-6.5873-2.95230.4426-0.8132-2.168-2.9385-0.9678-1.866-0.243-1.378889.35110.75870Single point of activity-4.97133.990.888280.6868-3.207930 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0157
Inactive043.2274-0.4217-5.36674.2879-0.76117.993-0.6172-2.95230.12040.2389-2.49690.367-2.94147.0059-0.88663.2274103.06540.600216-1.455840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.6692
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: 1011189
Protocol:
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00737 uMActivity at 0.034 uMActivity at 0.074 uMActivity at 0.160 uMActivity at 0.236 uMActivity at 0.363 uMActivity at 0.672 uMActivity at 0.802 uMActivity at 1.176 uMActivity at 1.813 uMActivity at 3.626 uMActivity at 4.165 uMActivity at 5.886 uMActivity at 9.068 uMActivity at 18.22 uMActivity at 21.24 uMActivity at 33.77 uMActivity at 45.94 uMActivity at 91.56 uMActivity at 107.6 uMActivity at 194.3 uMActivity at 231.0 uMActivity at 0.159 uMActivity at 0.360 uMActivity at 0.847 uMActivity at 1.840 uMActivity at 9.105 uMActivity at 21.25 uMActivity at 45.98 uMActivity at 107.7 uMActivity at 0.0002950000 uMActivity at 0.00135 uMActivity at 0.00295 uMActivity at 0.00640 uMActivity at 0.00942 uMActivity at 0.014 uM
Inactive26.025701.78850.999712.5-13.525740 0 0 0 1-16.4169-13.3547-10.0454.879911.8869-16.4169
Inhibitor11.220268.575810Single point of activity-4.954.0950.9841-51.897616.6782-30 0 0 0 0-51.769712.507722.751815.0653-4.0088-51.7697
Inhibitor7.0795112.066143Partial curve; high efficacy-5.151.88510.9823-103.18038.8859-2.10 0 0 0-95.53733.23779.0024-65.3012-95.5373
Inhibitor15.8489105.509342Partial curve; high efficacy-4.810.9579-114.0492-8.5398-2.10 0 0 0 0-90.5152-4.0803-11.1572-29.099-39.1247-90.5152
Inactive16.477501.3310.9615-2.5103-18.987941 0 0 0 0 0 1-16.3315-65.7135-14.9899
Inhibitor7.0795101.797683Complete curve; high efficacy-5.154.95490.9565-95.44826.3494-1.10 0 0 0 0-94.451620.9917-9.24498.049-74.805-94.4516
Inactive12.307103.06540.5785-22.7235-10.416540 0 0 0 0-26.853-10.7637-15.6935-26.1694-15.1194-26.853
Inhibitor0.089112.386510Complete curve; partial efficacy; poor fit-7.054.95490.364-34.6437-22.2572-1.40 0 0 0 0-37.9759-25.631-39.7031-25.7241-35.5044-37.9759
Inactive10.026404.44950.7108-12.3905-2.364140 0 0 0 1-7.3774-6.9326-0.3034-11.4012-11.9921-7.3774
Inactive29.146503.06540.67871.473-27.673640 0 0 0 0 0 1-21.724-27.2731-11.0127
Inactive25.21704.95490.4619-13.2171240 0 0 0 0-8.30867.9877-27.6808-0.1174-16.8896-8.3086
Inactive12.838204.95490.3995-3.393-16.231240 0 0 0 1-15.3571-15.1609-13.0051-20.6093-11.1608-15.3571
Inhibitor35.481326.237210Partial curve; partial efficacy; poor fit-4.454.95490.6657-53.1099-26.8727-2.40 0 0 0 0-47.5916-28.5919-36.8323-19.4772-23.3034-47.5916
Inactive7.543804.95490.8451-6.8775-14.421240 0 0 0 0-6.4743-14.3323-14.5177-4.8979-9.6517-6.4743
Inactive37.81404.95490.7329-20.885116.928840 0 0 0 0 0 1-3.613.1204-26.6275
Inactive13.166504.95490.6781-12.166540 0 0 0 00.861-4.7712-15.0697-16.8054-1.02860.861
Inactive6.235504.95490.32441-5.235540 0 0 0 02.3165-3.52964.2330.0986-3.45432.3165
Inactive15.475304.95490.9575-17.3357-1.860541 0 0 0 0-15.6395-25.4707-3.6337-19.0298-16.8468-15.6395
Inactive14.093800.90.9644-15.4586-1.364840 0 0 0 1-6.1352-1.1373-3.7059-5.1536-11.2155-6.1352
Inactive04-19.0793-27.1382-31.3978
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PPARGA972
Protocol: Tox21 Assay Protocol Summary:

PPARg-bla cells were dispensed at 3000 cells/6uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C for 17 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA), the plates were incubated at room temperature for 1 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001156673 uM-Replicate_1W460-Activity at 0.0002222558 uM-Replicate_1W460-Activity at 0.0004931235 uM-Replicate_1W460-Activity at 0.00104 uM-Replicate_1W460-Activity at 0.00231 uM-Replicate_1W460-Activity at 0.00516 uM-Replicate_1W460-Activity at 0.012 uM-Replicate_1W460-Activity at 0.026 uM-Replicate_1W460-Activity at 0.058 uM-Replicate_1W460-Activity at 0.129 uM-Replicate_1W460-Activity at 0.288 uM-Replicate_1W460-Activity at 0.642 uM-Replicate_1W460-Activity at 1.434 uM-Replicate_1W460-Activity at 3.198 uM-Replicate_1W460-Activity at 7.140 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 25.00 uM-Replicate_1W460-Activity at 54.78 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036788 uM-Replicate_1
Inactive045.42281.8804-1.53680.6322-0.2357-0.44520.7975-0.3858-1.01032.282-1.42024.9509-0.30931.48620.40195.4228104.95490.35122-1.451740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.1576
Inactive045.82145.22420.64251.8288-0.8085-5.16881.092210.98658.48039.20855.59025.4150.62772.64660.9385.8214104-1.1424
Inactive04-2.30724.5751-0.75450.930925.8242-2.107216.09821.02894.92540.437312.04393.5090.3752-1.6073-1.7588-2.30721043.0274
Inactive043.30734.59326.16091.4977-0.3069-7.99849.32760.43930.52646.24550.6765-1.14832.95142.83040.33553.30731040.8269
Inactive01.46410.36614-6.318740 0 0 0 0 0 0 0 0 0 0 0 0 0 014.1141-3.4381-7.3489-3.26415.9377-1.29136.0792.4574-0.66819.1174-1.99613.96474.54960.21062.435814.11411040.8076
Inactive04.44950.7601-7.3061-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.8849-2.0187-0.9161-0.9264-2.7952-0.4328-1.6855-0.3391-0.407-2.5735-1.49410.96480.9826-2.8423-8.5884-5.8849104-2.9291
Inactive010.830117-0.034840 1 0 0 0 0 0 0 0 0 0 0 0 0 014.0286-1.145431.0664-2.11240.7218-0.0209-0.52610.88461.37251.2826-0.56811.99398.35712.3512.86214.02861043.366
Inactive04-0.1819-7.0263-5.6511-1.9334-3.7135-3.6978-5.8053-1.5642.065-2.2268-16.5881-0.3846-7.6272-6.6085-1.2608-0.1819104-0.8667
Inactive044.42848.60874.2844.04556.64827.16785.820915.600711.20528.55338.08613.78917.55046.08934.2134.42841045.3451
Inactive04-8.88941.8737-2.22351.16232.8957-10.7195-1.00881.46140.00462.21452.95272.1393-0.7247-1.0202-1.027-8.8894104-1.7136
Inactive04.95490.4507-3.3961440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.4968-2.1527.83886.24711.14156.3871.65253.75036.13644.7998-8.8061-4.1072-2.40111.93952.6284-9.4968100.10.3228-6.7797240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.503
Inactive04-3.13693.33310.47570.23633.6413-1.1851.67973.84655.91537.55739.92998.6054-0.21813.92783.1089-3.1369104-2.15
Inactive04.95490.3773-4.36122.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.63430.7143-0.22365.48595.25581.75083.14210.64220.72592.48834.3837-0.00872.52846.69730.8788-3.6343104-0.2141
Inactive043.91723.01557.19690.74161.21654.60025.20565.944310.54471.99850.9756-0.07680.67112.53342.09523.9172104.95490.7847.50.279640 0 0 0 0 0 0 0 0 0 0 0 0 0 05.9565
Inactive045.8298-0.67512.41520.54165.239410.767-0.54651.59181.19133.81416.22981.75781.56111.41622.80265.8298104-0.4924
Inactive04-3.3157-1.35199.8672-1.63770.76281.52990.4097-1.04661.3819-1.6627-0.25360.405-1.83081.1677-1.1253-3.3157104.0950.7713-10.2663240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.5553
Inactive047.8599-1.29032.81650.11083.4806-1.3434-2.64223.52578.22935.90481.45342.15660.2133-0.63753.27987.8599104.95490.38052.5-0.395740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5909
Inactive04-0.4616-4.8308-0.9318-4.356-1.9238-0.7086-2.3682-1.3797-3.6392-1.95447.0786-5.846-0.1781-1.1608-5.1462-0.4616104-0.1454
Inactive04.95490.3247-4.0319-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.79930.54530.0785-1.5792-1.5775-0.3717-2.37460.07991.28960.8896-0.2455-11.6933-2.313-1.97130.1175-5.7993104-0.1597
Inactive04.95490.53848-1.30340 0 0 0 0 0 0 0 0 0 0 0 0 0 10.6277-3.7875-5.2525-0.92431.34540.91270.1311-0.388-1.0844-1.7767.31937.41056.141317.9007-0.5580.6277104-0.0463
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR001
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inactive000406.942202.372800.458305.80229.8216000QC'd by BIOMOL
Inactive00040000.78791.0771004.091704.998300QC'd by BIOMOL
Inactive0-7.37924.95490.41460.86115.540 0 0 0 0 0 0 0 0 0 01.837309.11175.53448.2389002.305104.4881-0.94911.8373QC'd by BIOMOL
Inactive0-5.17922.72020.8215-20.66392.540 0 0 0 0 0 0 0 0 0 1-6.09160-2.79660.22858.08152.5833.73547.32021.7166-5.5554-18.8865-6.0916QC'd by BIOMOL
Inactive00043.74957.22936.37145.613507.482901.69948.4113003.7495QC'd by BIOMOL
Inactive00046.36577.19537.3079001.87945.979907.4799006.3657QC'd by BIOMOL
Inhibitor14.81835.514921Partial curve; partial efficacy-4.82923.06540.9214-31.01494.5-2.20 0 0 0 0 0 0 0 0 0 0-30.42915.77728.87813.66834.2274.72228.01864.5719-4.21873.6532-13.8256-30.4291QC'd by BIOMOL
Inactive000405.78175.8939008.5995006.074406.5850QC'd by BIOMOL
Inactive0004-2.104508.25230-2.17247.221607.3601-2.8223-6.14464.4899-2.1045QC'd by BIOMOL
Inactive0-4.42924.95490.4721-18.4451.540 0 0 0 0 0 0 0 0 0 0-13.287507.01614.53755.0482005.2422-2.8732-8.90186.1541-13.2875QC'd by BIOMOL
Inactive00049.43850000.93210.52520009.489409.4385QC'd by BIOMOL
Inactive0004-1.189406.558504.48600.538104.86393.46642.4738-1.1894QC'd by BIOMOL
Inactive0-6.07924.95490.40475.50.155340 0 0 0 0 0 0 0 0 0 101.4724.5108000-2.787208.386408.06150QC'd by BIOMOL
Inactive0004000.71730.66792.56178.0704009.810508.97310QC'd by BIOMOL
Inactive00041.1339-2.329408.3935009.78267.57146.4163001.1339QC'd by BIOMOL
Inactive0-9.02924.95490.38982-12.787140 0 0 0 0 0 0 0 0 0 1-4.0609-8.98923.4212-1.75787.17160.61375.21776.7693.1957-7.1191-0.2144-4.0609QC'd by BIOMOL
Inhibitor20.931101.63441Partial curve; high efficacy-4.67924.0950.99-99.56492.069-2.10 0 0 0 0 0 0 0 0 0 0-91.68045.251107.629403.87461.2696000-20.7764-91.6804QC'd by BIOMOL
Inactive000402.320402.28163.4121.25641.61620000.22870QC'd by BIOMOL
Inactive0-4.57924.50450.7778-24.88853.540 0 0 0 0 0 0 0 0 0 0-22.82385.74268.64626.02173.77214.16569.06293.0606-1.1003-6.03351.2279-22.8238QC'd by BIOMOL
Inhibitor33.1734109.831210Single point of activity-4.47924.95490.9783-109.32610.505-30 0 0 0 0 0 0 0 0 0 0-91.5629-0.0109-1.05751.09492.26989.4465-3.45940-7.435400-91.5629QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRN257
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001158387 uM-Replicate_1W460-Activity at 0.0002261535 uM-Replicate_1W460-Activity at 0.0004949824 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00229 uM-Replicate_1W460-Activity at 0.00510 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.057 uM-Replicate_1W460-Activity at 0.127 uM-Replicate_1W460-Activity at 0.284 uM-Replicate_1W460-Activity at 0.634 uM-Replicate_1W460-Activity at 1.415 uM-Replicate_1W460-Activity at 3.154 uM-Replicate_1W460-Activity at 7.040 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 27.01 uM-Replicate_1W460-Activity at 58.48 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive04-12.097-15.4211.22518.50446.32020.846114.98991.67820.3453-2.12172.5147-17.8498-9.32760.28162.6709-12.097104-12.0519
Inconclusive0Single point of activity-4.52134.95490.372839.41940.385430 0 0 0 0 0 0 0 0 0 0 0 0 0 032.79711.95395.33912.21820.80081.884415.32420.02920.8207-21.1398-1.4369-24.04185.752217.14520.630832.79711040.9716
Inactive04-5.25290.17872.973832.766221.31856.600616.055125.63979.842634.3918-9.8497-0.1044-5.717114.7663-0.7047-5.25291046.6113
Cytotoxic23.914544.75320Partial curve; high efficacy-4.77133.06540.9397-151.36460.7993-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-140.15255.712-11.72013.174311.80043.9627-11.745919.69894.1037-4.89243.0574-21.16290.0911-4.4585-74.4823-140.15250Complete curve; high efficacy-4.97133.51170.8761-65.1981-0.3709-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.7954
Inhibitor26.8325102.2380Single point of activity-4.57134.95490.7068-122.91268.4508-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.83561.9814-8.2905-0.6801-2.507810.7911-7.456524.81948.5806-7.33822.7627-1.146220.661865.1802-2.288-103.83560Single point of activity-4.57134.95490.8259-97.04015.198-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.6797
Inactive043.352-18.3617-0.7198-1.82120.7254-2.3887-0.71138.1346-18.636610.8874-1.88711.636-16.58518.3351-18.83343.3521042.0179
Inconclusive0Complete curve; partial efficacy; poor fit-7.52131.46410.680236.20112.51.41 0 0 0 0 0 0 0 0 0 1 1 1 1 122.057130.60393.688701.975524.92820.940436.70837.549926.490437.73945.076219.601119.7132-3.264822.0571104-2.2828
Inactive043.5852-0.9953.1779-2.90782.9481-0.79636.8681-22.0598-14.2108-2.2977-16.3346-2.03172.00522.18690.90223.5852104-2.9287
Inactive04-2.74024.46784.162900.150523.553338.24690.453-5.2560.55339.8796-0.6274-4.2999023.1032-2.7402104-6.1592
Inactive0417.07540.24292.78673.44132.792-1.4151.419821.8245-2.16183.6162-18.04260.0956-1.3056-2.398512.358417.0754104-11.8022
Cytotoxic26.832542.81820Single point of activity-4.57134.95490.9428-140.4676.5416-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-123.21672.731110.1203-0.9412-0.006715.33822.152318.6872.49431.3665-0.576414.2545-2.3685-1.0992-1.3076-123.21670Partial curve; partial efficacy; poor fit-4.52130.60.588-65.2178-6.1658-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.7601
Inconclusive0Partial curve; partial efficacy-4.92131.10.711641.11172.152.20 0 0 0 0 0 0 0 0 0 0 0 0 0 040.5279-2.658815.3997-1.32051.54133.8511.1616-0.54452.66480.16530.4079-0.475322.922612.925317.4440.5279104-1.1211
Inactive045.3983-14.35172.32162.82171.398410.6583-13.337-1.73434.042716.340518.8055-0.856912.351214.0297-4.28015.3983104-15.3874
Cytotoxic26.832560.9510Single point of activity-4.57134.95490.8965-166.924610.764-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-155.4129-4.74481.248714.33939.9359-5.64392.083840.29660.993714.79787.97237.785523.56762.329620.0585-155.41290Single point of activity-4.57134.95490.72-34.1482.3048-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.286
Inactive04-17.9221-5.6935-9.7378-15.0242-13.45874.1955-20.9421.6642.78496.2808-1.65063.6358-21.3152-1.5804-17.7116-17.9221104-3.4006
Inactive04-16.0736-0.16670.063414.39452.22271.76036.0139-16.78778.30026.13620.2785-23.70580.041617.93561.9071-16.0736104-0.4858
Inactive00.70.515419.5726-16.145540 0 0 0 0 0 1 0 0 0 0 0 0 0 1-18.9267-14.0001-14.1391-15.825-18.1982-31.1347-5.992124.7447-16.7843-1.0696-18.5346-4.5707-4.9181-7.002213.1558-18.9267104-7.4051
Inactive04-15.437230.19180.87326.82955.19737.68435.82839.8057-1.3433-0.6271-0.7496-16.36081.435420.67980.2025-15.43721040.541
Inactive04-8.09546.20142.679-3.15441.45620.91-3.2719-6.17514.4834-9.2058-3.6067-5.2067-7.29356.5535-11.4671-8.0954104-19.5741
Inconclusive04-6.5078-13.7847-11.6608-0.2953-62.2272-22.8473-5.7475-4.5773-29.0585-18.6043-33.5711-11.69590-23.5243-23.2348-6.50780Single point of activity-4.57134.95490.701639.7004-8.651930 0 0 0 0 0 0 0 0 0 0 0 0 0 036.4575
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR002
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inhibitor4.109535.955421Complete curve; partial efficacy-5.38621.47870.9847-33.45542.5-1.20 0 0 0 0 0 0-32.46282.18335.970600-5.6126-25.295-32.4628QC'd by Axon Medchem
Inhibitor14.58134.657110Partial curve; partial efficacy; poor fit-4.83622.33320.9403-32.15712.5-2.40 0 0 0 0 0 0-29.71430007.41155.8195-6.9018-29.7143QC'd by Tocris
Inactive0-4.83621.86170.9256-16.65942.540 0 0 0 0 0 0-14.71612.62120.581.02516.28291.7864-3.3449-14.7161QC'd by Glixx
Inhibitor1.63666.161564Complete curve; partial efficacy-5.78622.72020.9997-65.81160.3499-1.20 0 0 0 0 0 0-66.50140000-37.9408-64.7373-66.5014QC'd by Glixx
Inactive0-4.63621.96730.7584-23.667-2.467140 0 0 0 0 0 0-19.3058-0.694-0.3893-3.2758-10.1148-2.3842-5.3061-19.3058QC'd by SIGMA
Inactive0-4.78623.06541-20.0675040 0 0 0 0 0 0-19.222900000-2.9492-19.2229QC'd by Axon Medchem
Inhibitor10.322547.836221Partial curve; partial efficacy-4.98621.88510.9724-41.83626-2.20 0 0 0 0 0 0-38.7819.20936.095507.71415.1385-14.8631-38.781QC'd by MedChem Express
Inactive00046.01782.42486.41361.896906.213206.0178QC'd by Tocris
Inhibitor29.092960.09310Single point of activity-4.53624.95491-60.03460.0584-30 0 0 0 0 0 0-54.4164000000-54.4164QC'd by Tocris
Inactive0004-6.543200000-1.4393-6.5432QC'd by Tocris
Inhibitor16.360136.851110Partial curve; partial efficacy; poor fit-4.78621.010.8986-32.35114.5-2.40 0 0 0 0 0 0-23.62598.789708.696100-7.2303-23.6259QC'd by Tocris
Inactive00049.2406001.75143.496707.9269.2406QC'd by Glixx
Inhibitor9.233.715210Partial curve; partial efficacy; poor fit-5.03621.41630.9706-30.21523.5-2.40 0 0 0 0 0 0-27.26265.31472.675106.30420-12.9935-27.2626QC'd by Tocris
Inhibitor16.360152.695221Partial curve; partial efficacy-4.78621.28760.9602-49.04213.653-2.20 0 0 0 0 0 0-37.79029.1493005.18520-13.7877-37.7902QC'd by Tocris
Inactive0-4.78624.44950.9565-27.1196340 1 0 0 0 0 0-26.76640-80.85495.97525.378600.9575-26.7664QC'd by Tocris
Inhibitor0.580574.818526Complete curve; partial efficacy-6.23623.67720.9839-72.75452.064-1.20 0 0 0 0 0 0-64.73751.50932.14072.7381-9.5317-70.5587-81.6221-64.7375QC'd by MedChem Express
Inhibitor18.356499.324110Single point of activity-4.73623.62720.9917-97.78141.5427-30 0 0 0 0 0 0-94.201708.64420-1.04460-6.3447-94.2017QC'd by Tocris
Inhibitor29.092985.830210Single point of activity-4.53624.95490.9979-84.3311.4991-30 0 0 0 0 0 0-76.60620.5645002.14332.14953.4024-76.6062QC'd by MedChem Express
Inhibitor12.995349.172121Partial curve; partial efficacy-4.88622.25260.9678-45.67253.4996-2.20 0 0 0 0 0 0-42.17617.83150.28501.26966.3138-12.2728-42.1761QC'd by Tocris
Inactive0-4.68621.88510.8683-38.0965-12.016740 0 0 0 0 0 0-33.4065-7.5139-13.5025-14.684-16.035-8.8732-16.7676-33.4065QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: GRV193
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature (RT) for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). After measurement of bla assay, 3 ul CellTiter-Glo (Promega, Madison, WI) was added to measure the cytotoxicity and the plates were then incubated at RT for 30 min. The luminescence was measured using a ViewLux (Perkin Elmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000036780 uM-Replicate_1Activity at 0.0000082250 uM-Replicate_1Activity at 0.0000183900 uM-Replicate_1Activity at 0.0000514202 uM-Replicate_1Activity at 0.0001156673 uM-Replicate_1Activity at 0.0002261535 uM-Replicate_1Activity at 0.0004949824 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00229 uM-Replicate_1Activity at 0.00510 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.284 uM-Replicate_1Activity at 0.634 uM-Replicate_1Activity at 1.415 uM-Replicate_1Activity at 3.154 uM-Replicate_1Activity at 7.040 uM-Replicate_1Activity at 15.11 uM-Replicate_1Activity at 27.01 uM-Replicate_1Activity at 58.48 uM-Replicate_1Activity at 78.95 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-8.9896-7.3975-6.7113-14.8241-4.5178-1.517512.264-8.1607-13.49270.92690.0472-1.09210.2383-2.6378-1.9489-8.9896QC'd by SequoiaCytotoxic0.006727.901520Complete curve; partial efficacy; poor fit-8.17134.95490.4115-26.6818
Inactive04-12.8644-12.4335-6.4744-20.0821-10.89713.6433-6.8703-5.7214-9.84543.7236-7.371-2.7049-10.4097-16.8792-5.8495-12.8644QC'd by FLUKAInactive0
Inactive00.60.6935-5.705513.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.93149.184113.869-0.63448.33090.23784.4977-4.6175-6.73290.5376-2.5323-8.0879-5.8972-4.0555-7.5668-2.9314QC'd by FLUKACytotoxic47.715650.274420Partial curve; partial efficacy; poor fit-4.32130.30.4501-54.3952
Inactive0412.0884-2.3949-3.4828-3.133815.632524.520517.03-4.6009-4.4756-1.6879.12462.7279-2.11843.193-0.18912.0884QC'd by BIOMOLInconclusive1.068269.039710Partial curve; partial efficacy; poor fit-5.97130.20.438955.7277
Cytotoxic26.832573.745320Single point of activity-4.57134.95490.8323-69.69384.0515-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.368517.6007-1.759413.0949-3.274312.563612.30281.95770.648-6.95350.28381.5448-0.0522-1.42575.7042-61.3685QC'd by BIOMOLCytotoxic21.313893.273741Partial curve; high efficacy-4.67132.90230.9235-86.9043
Inactive046.7909-1.31027.7383-4.547-2.65212.1059-2.4181-1.10118.09747.2420.3477-5.05879.40029.3931-0.87996.7909QC'd by BIOMOLInactive0
Inactive041.4423-3.99322.77927.1221-0.8837-8.95352.295-0.51041.37322.285720.59571.5207-5.3744.2397-11.91461.4423QC'd by BIOMOLInactive0
Inactive00.60.3367-9.79324.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.02261.3465-0.45472.410510.291411.99868.0638-8.1616.00951.6819-2.0122-2.01511.6093-6.3684-6.20422.0226QC'd by BIOMOLInactive02.47290.378538.7776
Inactive0415.2343-1.80842.058715.92577.90848.0244-2.30815.36692.48331.03819.9575-3.366-5.2227-2.2446-0.160715.2343QC'd by BIOMOLInactive0
Inactive047.9538-1.872810.9648-1.09872.6071-1.078614.35211.0497-1.76951.8577-2.7126-2.4267-0.2948-1.380911.52387.9538QC'd by BIOMOLInconclusive18.995953.670810Partial curve; partial efficacy; poor fit-4.72132.40640.570554.7236
Inactive04.95490.518517.50.289140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.283514.4715-2.8018-2.2504-1.854-1.0751.91726.8822-1.1544-5.5924-0.0354-3.34427.78934.034525.595213.2835QC'd by BIOMOLInactive0
Inactive049.45185.1439-10.9187-3.6004-4.60710.015617.848513.801-6.53560.5436-3.981315.85290.99558.7778-0.51489.4518QC'd by BIOMOLInconclusive0.169342.502710Single point of activity-6.77133.92950.653739.4606
Inactive041.8471-10.88334.52062.79765.23563.9098-5.1881-2.0961-0.0954-3.919-3.2093-1.8064-33.7228-4.1242-0.88821.8471QC'd by BIOMOLInactive04.95490.31142.5
Inactive044.8349-4.63776.5338-3.86720.3182-6.07670.8186-2.79026.0128-0.779714.731111.52557.4133-0.9249-2.93594.8349QC'd by BIOMOLInactive04.95490.371213.3777
Inactive04-4.067912.1355-8.423722.677520.0333.0761-4.23854.78041.17568.42751.9834-7.49172.3009-2.1910.399-4.0679QC'd by BIOMOLInconclusive0.016923.312910Complete curve; partial efficacy; poor fit-7.77134.95490.334218.2886
Inactive042.05745.26574.3417-5.6188-2.5518-0.73413.2906-1.1924-0.81874.4295-6.552710.0188-0.8658-4.17642.45482.0574QC'd by BIOMOLInactive0
Inactive048.5616-2.0682-0.46498.21222.20687.6990.2449-0.087712.19887.0464-0.3008-1.4858-2.93310.76220.39078.5616QC'd by BIOMOLInactive0
Cytotoxic6.00796.604783Complete curve; high efficacy-5.22134.95490.9827-93.96262.6422-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.07621.3064-6.14065.13090.1256-0.83290.3014-0.60629.61044.55867.1299-0.84948.1454-69.6407-92.7982-96.0762QC'd by BIOMOLCytotoxic5.353889.607684Complete curve; high efficacy-5.27134.95490.9148-95.5166
Inactive04-3.2987-4.8177-8.49767.47813.7599.2959-2.2766-1.27941.7611-5.167216.38672.699710.28948.2038-9.5775-3.2987QC'd by BIOMOLInconclusive0.030119.213610Complete curve; partial efficacy; poor fit-7.52134.95490.332612.8869
Inactive048.7339-1.21470.07750.0749-2.3291-0.54618.96933.3015-2.1752-15.4981-13.43471.2297-0.91132.62215.99288.7339QC'd by BIOMOLInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PLD386
Protocol: Assay Protocol Summary:

HepG2 cells are dispensed at 900 cells/3 uL/well into Collagen I-coated 1536-well black-wall/clear-bottom assay plates (Greiner Bio-One, Monroe, NC) using the Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). The assay plates are incubated at 37 C for 4 hours to allow the cell attachment. 3 uL of 1:500 LipidTOX Red dye is added using the dispenser, and then 23 nL compounds are added via a Wako Pintool station (Wako Automation, San Diego, CA). Amiodarone, a known PLD inducer, was used as a positive control and DMSO was used as a negative control. The assay plates were then incubated at 37 C for 24 hours.

For fixations, 4 uL of 8% paraformaldehyde fixative solution containing 10 ug/mL Hoechst 33342 in Dulbecco's phosphate-buffered saline (DPBS) is added using a Kalypsys washer/dispenser (Kalypsys, San Diego, CA, USA). After incubation at room temperature for 30 min, the assay plates are washed once with DPBS using a Kalypsys washer/dispenser. The assay plates are then sealed and stored at 4 C before imaging. The fluorescence intensities (595 nm excitation, 615 nm emission for LipidTOX; 352 nm excitation, 461 nm emission for Hoechst 33342) are measured using an ImageXpress Micro Widefield High Content Screening System (Molecular Devices, Sunnyvale, CA, USA) with a 20x Plan Fluor objective. Images are acquired for one site in each well and analyzed with the MetaXpress software (Molecular Devices) using the Transfluor module. Several algorithmic outputs, such as pit count per well, pit count per cell, pit integrated intensity per well, and pit integrated intensity per cell, are used for quantitative image analysis for PLD.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00559 uMActivity at 0.012 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.059 uMActivity at 0.137 uMActivity at 0.153 uMActivity at 0.306 uMActivity at 0.612 uMActivity at 0.710 uMActivity at 1.532 uMActivity at 3.148 uMActivity at 4.894 uMActivity at 7.662 uMActivity at 15.53 uMActivity at 19.04 uMActivity at 38.30 uMActivity at 69.89 uMActivity at 78.45 uMActivity at 150.9 uMActivity at 192.2 uMCompound QC
Inactive040.52250.9197-0.2148-3.0798-0.7670.5225QC'd by NCI
Inactive04.95490.8575-2.5047240 0 0 0 0-1.01231.96521.94551.9624-3.7539-1.0123QC'd by NCI
Inactive03.92950.83390.0205640 0 0 0 0-0.59373.8164-1.23290.78590.4134-0.5937QC'd by NCI
Inactive040.409-0.922-0.3836-0.40790.28520.409QC'd by SigmaAldrich
Inactive01.210.57212.5-3.682440 0 0 0 02.3849-1.4022.82760.22324.62172.3849QC'd by NCI
Inactive044.1808-1.330312.1123-1.67094.93474.1808QC'd by NCI
Inactive04-0.1837-0.95772.373-1.54381.4476-0.1837QC'd by NCI
Inactive040.46912.01460.25580.34690.4350.4691QC'd by NCI
Inactive04.50450.94036-0.886640 0 0 0 05.8940.1078-1.9889-1.3913-0.60335.894QC'd by NCI
Activator28.183821.270410Partial curve; partial efficacy; poor fit-4.554.95490.994720.5-0.77042.40 0 0 0 016.7877-1.4632-0.6573-0.2313-1.475416.7877QC'd by Labotest
Inactive04-0.1246-1.73481.1946-0.6236-2.6757-0.1246QC'd by NCI
Inactive04-1.78780.0388-2.7225-2.2048-3.4121-1.7878QC'd by NCI
Inactive04.95490.7197-1.20362.540 0 0 0 0-0.44512.63960.68823.5768-2.253-0.4451QC'd by NCI
Activator8.912523.358910Partial curve; partial efficacy; poor fit-5.053.06540.991522-1.35892.40 0 0 0 021.82270.1626-2.3824-1.40577.419521.8227QC'd by NCI
Inactive041.0997-1.7227-0.835.0E-4-0.03191.0997QC'd by NCI
Inactive044.0416-0.1081-0.36380.1442-0.67394.0416QC'd by NCI
Inactive01.06410.9939-6.19520.540 0 0 0 11.19570.784-0.0956-1.6108-4.32931.1957QC'd by NCI
Inactive04-0.2978-0.07670.61.2943-0.2232-0.2978QC'd by Chembridge
Inactive041.282-0.3951-1.4501-0.0311-2.36261.282QC'd by NCI
Inactive02.40640.31175-240 0 0 0 07.0020.90276.95040.35115.08377.002QC'd by NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:glucocorticoid receptor [Homo sapiens]
External ID: GRA646
Protocol: Please refer to other AIDs 720691, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the GR agonist mode assay (AID 720691) and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inconclusiveinconclusive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist26.2133798280.63773882active antagonist23.36269936-80.71273442active antagonist26.21337982-33.67998135inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inconclusive agonist0inconclusive agonist0inactiveSigmaAldrich
inconclusiveinconclusive agonist25.01773299170.756549active antagonist26.21337982-71.55109769inconclusive antagonist26.83246391-39.31724907inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist14.2449376949.76333982active antagonist13.44808836-78.84104162inconclusive antagonist13.44808836-40.31184202inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MALG0567
Protocol: The 1536-well gametocycidal viability assay was based on the previous method of Tanaka et al. Stage III-V gametocytes were tested against three compound libraries, including 4265 compounds from NCGC pharmaceutical collection, 400 from Malaria Box library, and 550 from an internal collection of kinase inhibitors. Briefly, 2.5 ul/well incomplete medium was dispensed into each well of 1,536-well plates using the Multidrop Combi followed by 23 nl compound transferring using the NX-TR Pintool (WAKO Scientific Solutions, San Diego, CA). Then, 2.5 ul/well of gametocytes was dispensed with a seeding density of 20,000 cells/well using the Multidrop Combi. The assay plates were incubated for 72 h at 37C with 5% CO2. After addition of 5 ul/well of 2X AlamarBlue dye (Life Technologies, cat. no. DAL1100), the plates were incubated for 24 h at 37C with 5% CO2 and then were read in a fluorescence detection mode (Ex = 525 nm, Em = 598 nm) on a ViewLux plate reader (PerkinElmer).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003541572 uMActivity at 0.0007804147 uMActivity at 0.00128 uMActivity at 0.00234 uMActivity at 0.00384 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.035 uMActivity at 0.063 uMActivity at 0.086 uMActivity at 0.182 uMActivity at 0.258 uMActivity at 0.417 uMActivity at 0.795 uMActivity at 1.685 uMActivity at 1.846 uMActivity at 4.638 uMActivity at 6.957 uMActivity at 10.66 uMActivity at 19.94 uMActivity at 31.13 uMActivity at 46.10 uMActivity at 93.93 uMActivity at 172.6 uMActivity at 231.0 uMCompound QC
Inhibitor0.0935154.693598Complete curve; high efficacy-7.02921.10.9814-146.09978.5938-1.10 0 0 0 0 0 0 0 0 0 0-149.38620.82076.86470.67910.9782-67.4006-102.1412-114.8055-133.0402-148.3233-149.2304-149.3862QC'd by "SigmaAldrich"
Inhibitor0.0469131.670797Complete curve; high efficacy-7.32920.70.9736-119.008512.6622-1.10 0 0 0 0 0 0 0 0 0 0-121.68564.93681.0179-2.144-47.6702-70.9047-78.6554-87.469-105.5788-116.3017-120.6225-121.6856QC'd by "Selleck"
Inhibitor0.006684.929296Complete curve; high efficacy-8.17921.24750.9877-84.92290.0063-1.10 0 0 0 0 0 0 0 0 0 0-77.5181-4.1745-21.34-41.4231-70.152-80.9864-85.8591-89.0178-86.9489-85.5856-83.0404-77.5181QC'd by "JohnsHopkins"
Inhibitor0.0118100.443395Complete curve; high efficacy-7.92921.17050.9878-84.899215.5441-1.10 0 0 0 0 0 0 0 0 0 0-90.70436.01479.5802-21.2099-53.734-69.8068-77.6527-79.6422-83.2532-88.1242-85.5758-90.7043QC'd by "Sequoia"
Inhibitor0.1663141.633695Complete curve; high efficacy-6.779210.9892-128.120413.5132-1.10 0 0 0 0 0 0 0 0 0 0-136.880711.867813.26622.2436-0.5908-17.7219-67.808-96.5304-112.4202-110.9171-129.8866-136.8807QC'd by "SigmaAldrich"
Inhibitor0.02790.554594Complete curve; high efficacy-7.5683.67720.999-89.81350.741-1.10 0 0 0 0 0 0 0 0 0 0-90.52050.756-0.846-5.0661-74.8914-87.6289-88.7218-88.3319-90.532-91.8339-90.0059-90.5205QC'd by "Tocris"
Inhibitor0.0662106.764594Complete curve; high efficacy-7.17921.46410.9837-103.23573.5288-1.10 0 0 0 0 0 0 0 0 0 0-116.25651.369-0.79760.2847-4.5164-54.339-80.5065-91.6482-99.3613-100.5238-104.506-116.2565QC'd by "NIEHS"
Inhibitor0.1177115.843894Complete curve; high efficacy-6.92921.34430.9819-117.1061-1.2623-1.10 0 0 0 0 0 0 0 0 0 14.4447-8.7321-5.1555-2.07771.9174-43.5671-78.2683-95.3251-115.0348-115.5958-124.31654.4447QC'd by "NIEHS"
Inhibitor0.1663128.528994Complete curve; high efficacy-6.77921.64360.9725-126.38822.1407-1.10 0 0 0 0 0 0 0 0 0 0-140.4313-2.80441.08562.28212.0499-14.3651-81.7532-101.0222-105.8782-121.507-138.7623-140.4313QC'd by "Labotest"
Inhibitor0.3034145.50894Complete curve; high efficacy-6.5182.35310.9645-139.58025.9278-1.10 0 0 0 0 0 0 0 0 0 0-164.98844.15414.02912.82374.3784-1.5742-93.6828-111.7838-118.1332-141.2241-150.3446-164.9884QC'd by "Vitas"
Inhibitor0.046988.34293Complete curve; high efficacy-7.32921.37230.9544-92.1654-3.8235-1.10 0 0 0 0 0 0 0 0 0 0-108.9426-13.2844-3.52390.2999-25.2059-64.7136-72.735-81.7312-84.6404-88.6351-94.7673-108.9426QC'd by "Microsource"
Inhibitor0.070832.349393Complete curve; high efficacy-7.150.40.9998-98.5263-130.8756-1.10 0 0 1-108.6376-109.4797-105.4246-102.5219-108.6376QC'd by "SigmaAldrich"
Inhibitor0.3722118.810292Complete curve; high efficacy-6.42921.10.9935-121.9435-3.1333-1.10 0 0 0 0 0 0 0 0 0 0-127.8234-11.3494-2.0872-2.6541-4.2104-15.8158-42.2192-78.7861-98.358-113.5802-117.5418-127.8234QC'd by "Selleck"
Inhibitor0.0743100.381492Complete curve; high efficacy-7.12921.46410.9876-89.042711.3387-1.10 0 0 0 0 0 0 0 0 0 0-93.33627.85819.74257.1857.3252-40.3237-66.2343-77.2974-84.8773-91.5077-92.181-93.3362QC'd by "SigmaAldrich"
Inhibitor0.1177102.295191Complete curve; high efficacy-6.92922.84730.9829-89.915512.3796-1.10 0 0 0 0 0 0 0 0 0 0-107.81236.963711.333312.195915.9836-1.5088-68.4419-83.4615-85.0976-87.4056-86.2068-107.8123QC'd by "Selleck"
Inhibitor0.046978.700691Complete curve; high efficacy-7.32923.51170.9854-79.7585-1.0579-1.10 0 0 0 0 0 1 0 0 0 0-89.8181-1.896-2.2203-0.0692-4.0216-61.5743-70.2002-2.1835-77.3305-78.9929-81.1936-89.8181QC'd by "Selleck"
Inhibitor0.3722123.853591Complete curve; high efficacy-6.42921.98870.9819-117.34696.5066-1.10 0 0 0 0 0 0 0 0 0 0-135.81822.82056.83845.11828.77272.6009-16.0727-85.914-98.5339-110.3252-113.4396-135.8182QC'd by "Toronto Research"
Inhibitor0.132193.841691Complete curve; high efficacy-6.87921.1110.9849-90.79593.0457-1.10 0 0 0 0 0 0 0 0 0 0-97.0042-5.34864.51841.4758-0.154-26.7948-59.3019-70.7041-80.6367-87.9767-91.0336-97.0042QC'd by "Prestwick Chemical; Inc."
Inhibitor0.316250.397691Complete curve; high efficacy-6.54.50450.9153-108.343-57.9454-1.10 0 0 0-104.8035-91.6212-110.7025-109.4596-104.8035QC'd by "SigmaAldrich"
Inhibitor0.083385.877291Complete curve; high efficacy-7.07922.18760.9957-84.49741.3799-1.10 0 0 0 0 0 0 0 0 0 0-80.2092-2.63883.18312.9768-5.1792-26.4406-72.7929-83.6942-88.0181-86.4306-84.6422-80.2092QC'd by "Sequoia"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:aryl hydrocarbon receptor [Homo sapiens]
External ID: AHR641
Protocol: Please refer to other AIDs, 743085 and 743086, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the AhR agonist mode assay (AID 743085) and cell viability counter screen (AID 743086). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAhR ActivityAhR Potency (uM)AhR Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inconclusive antagonistNCI
active agonistactive agonist17.7800949372.1655549inactive0NCI
active agonistactive agonist16.785492153.3983333inactive0SigmaAldrich
active agonistactive agonist10.5909294662.59572388inconclusive antagonistNCI
inconclusive agonistinconclusive agonistinactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist26.603212-58.81280317NCI
active agonistactive agonist16.78549286.16707887inactive0Labotest
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist25.11505164-82.62778849NCI
inactiveinactive0inactive0NCI
active agonistactive agonist7.49780386349.18407456inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
active agonistactive agonist26.603212132.2186995inactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:glucocorticoid receptor [Homo sapiens]
External ID: GRN811
Protocol: Please refer to other AIDs, 720692 and 720693, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the GR antagonist mode assay (AID 720692) and cell viability counter screen (AID 720693). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inconclusiveinconclusive0inactive0inactive0inactive0SIGMA
inactiveinactive0inactive0inactive0inactive0ChromaDex
inactiveinactive0inactive0inactive0inactive0SigmaAldrich
inactiveinactive0inactive0inactive0inactive0SIGMA
inconclusive antagonist (cytotoxic)inconclusive antagonist54.32986718-87.76367425inactive0inconclusive antagonist38.46260043-113.7483036inconclusive antagonist57.5491142-78.66380585SIGMA
inactiveinactive0inactive0inactive0inactive0SigmaAldrich
inconclusive antagonist (cytotoxic)inconclusive antagonist54.84690427-90.2091087inactive0inconclusive antagonist54.84690427-145.955503inconclusive antagonist54.84690427-76.23077822SIGMA
inactiveinactive0inactive0inactive0inactive0SV Chembiotech
inconclusiveactive agonist51.70269606356.960073inconclusive antagonist43.50239728-85.55782678active antagonist54.76627341-163.0950759active antagonist54.76627341-124.5386082SigmaAldrich
inactiveinactive0inactive0inactive0inactive0SIGMA
inconclusive antagonistinconclusive antagonist9.503923932-39.41427926inconclusive antagonist30.05404633-34.73053213active antagonist23.87277757-94.90808318inactive0SIGMA
inactiveinactive0inactive0inactive0inactive0SigmaAldrich
inconclusiveinconclusive0active antagonist56.44143314-71.76209279active antagonist37.00536561-155.5623704active antagonist56.44143314-113.2025902ChemService
inactiveinactive0inactive0inactive0inactive0SigmaAldrich
inactiveinactive0inactive0inactive0inactive0TCI
inactiveinactive0inactive0inactive0inactive0SIGMA
inactiveinactive0inactive0inactive0inactive0SIGMA
inactiveinactive0inactive0inactive0inactive0SIGMA
inactiveinactive0inactive0inactive0inactive0SIGMA
inactiveinactive0inactive0inactive0inactive0SigmaAldrich
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a [Homo sapiens]
External ID: AROS634
Protocol: Please refer to other AIDs, 743083 and 743084, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the aromatase antagonist mode assay (AID 743083) and cell viability counter screen (AID 743084). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAntagonist ActivityAntagonist Potency (uM)Antagonist Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist15.5453585-115.8029094active antagonist14.96008549-76.82181708NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist28.72548756-95.38057373active antagonist26.603212-99.89744711SigmaAldrich
inconclusive antagonist (cytotoxic)inconclusive antagonist33.49145963-46.25002522active antagonist23.71013766-54.80300837NCI
inconclusive agonistinconclusive agonist8.41267430127.57354485inactive0NCI
inactiveinactive0inactive0NCI
inconclusive agonistinconclusive agonist29.8492948130.54779271inactive0NCI
inactiveinactive0active antagonist27.64399095-51.49611017NCI
inconclusive antagonistinconclusive antagonist17.78009493-26.88101968inactive0Labotest
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist28.17955142-98.72733918active antagonist28.72548756-87.48306NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40657
Protocol: Tox21 Assay Protocol Summary:

300 DT40 mutant cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00617 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.535 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.01123.097-15.61374.831817.24522.68492.87025.838-1.15092.4566-15.0143-1.83128.71463.75322.72683.0112QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.1785-10.892-15.6985-0.69210.4103-15.63332.8403-15.8637-6.5703-13.149-26.3626.1142-10.7498-15.5641-24.2196-2.1785QC'd by Sigma DiscoveryCPRCytotoxic68.589691.523642Partial curve; high efficacy-4.16373.24750.8975-95.1787
Inactive04-10.4836-24.2062-15.4625-22.1853-17.0029-23.7071-26.4511-5.4538-39.9631-45.6107-35.4677-32.0907-29.217-24.9641-27.9971-10.4836QC'd by Sigma DiscoveryCPRCytotoxic61.130629.401520Partial curve; partial efficacy; poor fit-4.21371.88510.8107-31.9015
Inactive04-4.59729.3751-8.1926-3.89550.6461-8.566213.4774-0.62345.5343-3.2761-6.0086-5.24710.8659-3.3104-0.8139-4.5972QC'd by Sigma DiscoveryCPRInactive04.95490.6911-27.7726
Inactive01.3310.4841-18.2848-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4341-15.6941-0.6359-0.217-0.01279.76010.47981.0579-3.8901-4.4074-0.2904-14.3809-1.6368-26.0707-15.5655-15.4341QC'd by Sigma DiscoveryCPRCytotoxic68.589696.936120Single point of activity-4.16374.95490.9116-96.8607
Cytotoxic68.589648.251420Single point of activity-4.16374.50450.669-42.75145.5-30 0 0 0 0 0 0 0 0 0 0 1 0 0 0-32.76366.68717.171221.5873-4.0029-2.3442-2.24135.53994.60832.4453-0.50548.148-24.60336.40680.6319-32.7636QC'd by Sigma DiscoveryCPRCytotoxic68.589648.174420Single point of activity-4.16374.95490.9289-45.8879
Inactive00.30.7121-33.8051140 0 0 0 0 0 0 0 0 0 0 1 0 0 0-24.382310.43845.12726.81657.22591.8658-8.6709-16.2528-6.24420.3161-1.6373-7.5312-91.6148-26.0875-17.5667-24.3823QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic30.637967.376140Partial curve; high efficacy-4.51370.90.775-65.03912.337-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-60.304212.047412.9559-2.1973-12.63497.3969-3.88253.660712.6478-6.4422-9.9361-12.776-9.7544-22.4301-24.4994-60.3042QC'd by Sigma DiscoveryCPRCytotoxic61.130636.052220Partial curve; partial efficacy; poor fit-4.21374.95490.8632-33.5522
Cytotoxic61.1306111.553142Partial curve; high efficacy-4.21373.990.9734-113.6335-2.0804-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.65118.3666-2.0713-3.7808-2.35050.04213.1312-0.1348-6.3457-2.025-7.1259-0.3043-6.8314-6.1688-21.3977-95.6511QC'd by Sigma DiscoveryCPRInactive0
Inactive04-12.7888-1.057-2.0848-0.7554-6.8445-0.3896-2.5669-0.3877-3.83473.37538.0661-13.2548-2.828516.492-3.484-12.7888QC'd by Sigma DiscoveryCPRInactive01.69240.56086
Cytotoxic68.5896120.709842Partial curve; high efficacy-4.16374.95490.9332-122.3541-1.6443-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.4749-0.52770.547410.1427-1.25254.012-10.9614-1.4029-7.26650.8155-18.27654.3116-4.27371.9509-11.5455-99.4749QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6075-28.619-440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.4325-14.8758-0.7818-11.7063-0.11123.04971.97010.8638-15.4171-14.52550.3742.40541.2793-11.955-27.2415-28.4325QC'd by Sigma DiscoveryCPRInactive0
Inactive04.95490.6053-25.3863340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.9053-3.0798-0.16165.81434.36872.6264-2.68023.478213.64463.777-0.6631-2.940811.09824.56250.5366-19.9053QC'd by Sigma DiscoveryCPRInactive0
Inactive04-2.2887-9.33222.806-1.96982.835-19.1802-2.244-2.376111.6639-4.3953-0.88963.7875-1.1556-17.5934-15.146-2.2887QC'd by Sigma DiscoveryCPRInactive04.95490.74112
Cytotoxic68.5896121.561120Single point of activity-4.16374.95490.9451-122.6489-1.0878-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-100.2033-11.91628.5759-4.0103-8.04752.09744.9269-4.8191-8.6034.1695-6.8431-3.09872.96934.092-4.7679-100.2033QC'd by Sigma DiscoveryCPRInactive0
Inactive00.60.4241-16.80689.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.33918.7614-0.1122-2.521314.32534.912525.50638.89340.001311.5099-6.67791.0565-0.13852.7506-11.651-12.339QC'd by SIGMACytotoxic20Single point of activity
Inactive00.50.4566-0.24781040 0 0 0 0 0 0 0 0 0 0 0 0 0 02.05936.68268.657811.23617.42261.45222.14479.27011.79030.5244-3.08084.58743.84151.4091-6.45652.0593QC'd by Sigma DiscoveryCPRInactive04.0450.6801-25.4596
Inactive04.95490.4416-12.802440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.75170.2533-2.853315.69095.351413.8457-0.7219-3.2206-0.93875.440912.5372-1.28440.86326.1393-10.3064-12.7517QC'd by Sigma DiscoveryCPRInactive0
Inactive01.64360.3324-17.01442.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.845410.67053.9496.78270.3479-1.2699-8.220512.82270.96571.1019-3.13092.35830.7293-0.3373-3.38-10.8454QC'd by Sigma DiscoveryCPRInactive0
Cytotoxic0.136975.828189Complete curve; high efficacy-6.86371.46410.9678-76.2529-0.4248-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.61070.6376-4.1922-1.0881-0.5964-10.0644-14.6504-42.7191-72.2882-55.2459-69.9677-74.6041-73.5035-77.875-80.4615-83.6107QC'd by Sigma DiscoveryCPRCytotoxic0.216966.648687Complete curve; high efficacy-6.66374.95490.9621-68.4642
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:peroxisome proliferator activated receptor gamma [Homo sapiens]
External ID: PPARGA506
Protocol: Please refer to other AIDs 743094, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the PPARg agonist mode assay (AID 743094) and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0inactiveSigma DiscoveryCPR
inactiveinactive0inactive0inactive0inactiveSigma DiscoveryCPR
inactiveinactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactiveSIGMA
inconclusiveinconclusive agonist38.89524834145.0340014inconclusive antagonist34.66542657-89.3174655inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
inconclusiveinconclusive antagonistinactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
active agonistactive agonist38.8952483433.41701776inactive0inconclusive agonist30.8955939551.13359344inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inconclusive antagonistinactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactivePfizer
inactiveinactive0inactive0inactive0inactivePfizer
inactiveinactive0inactive0inactive0inactivePfizer
inconclusiveactive antagonist-17.45230439inactive0inactive0inactivePfizer
inactiveinactive0inactive0inactive0inactivePfizer
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: DT40653
Protocol: Tox21 Assay Protocol Summary:

300 DT40 wild type cells in 5 uL/well were dispensed into white, solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C/5% CO2 for approximately 0.5 hour, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred into the assay plate by a pintool work station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C/5% CO2 for 40 hours. After 5 uL per well of CellTiter-Glo reagent was added into each well of the assay plates, the plates were incubated for 30 min at room temperature and the luminescence intensity of the plates was measured using a ViewLux (PerkinElmer, Shelton, CT) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002694481 uM-Replicate_1Activity at 0.0005944760 uM-Replicate_1Activity at 0.00124 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00616 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.069 uM-Replicate_1Activity at 0.154 uM-Replicate_1Activity at 0.343 uM-Replicate_1Activity at 0.767 uM-Replicate_1Activity at 1.711 uM-Replicate_1Activity at 3.817 uM-Replicate_1Activity at 8.521 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 31.39 uM-Replicate_1Activity at 68.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Cytotoxic26.603236.966420Partial curve; partial efficacy-4.57512.72020.8066-39.4664-2.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.472-0.25570.1894-1.0942-0.5827-4.2967-5.868-6.7254-11.93875.14311.8075-4.2794-0.4027-4.0199-15.1045-32.472QC'd by BIOMOLCytotoxic29.849326.509520Partial curve; partial efficacy; poor fit-4.52512.63840.9875-26.5095
Inactive01.86170.797812.5-1.95440 0 0 0 0 0 0 0 0 0 0 0 0 0 013.436-3.4844-0.2195-0.0323-3.9215-4.0814-0.0401-0.8641-1.671-6.21177.13323.394912.058516.39137.133513.436QC'd by LabotestInactive0
Cytotoxic33.491572.589320Single point of activity-4.47514.95490.87-70.09812.4912-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.7558-5.4321-0.79632.7012-4.9918-9.0E-40.18971.83576.58097.28190.48664.686-3.50518.42064.2376-61.7558QC'd by NIEHSCytotoxic33.491548.466820Single point of activity-4.47514.95490.915-47.5343
Cytotoxic33.491562.335220Single point of activity-4.47514.95490.9666-60.31812.0171-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.91061.26516.74810.56595.4752-0.56413.2722-2.04112.0693-0.9569-1.23341.81252.32623.2022-1.746-52.9106QC'd by SigmaAldrichCytotoxic33.491555.158120Single point of activity-4.47514.95490.9353-53.8129
Cytotoxic0.059689.024292Complete curve; high efficacy-7.22511.78850.992-89.7743-0.75-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.2674-0.2675-0.0127-3.3186-0.3113-8.6624-24.8555-49.0768-77.442-90.0161-91.8738-92.0934-92.3604-91.6897-87.2484-79.2674QC'd by SigmaAldrichCytotoxic0.094489.564392Complete curve; high efficacy-7.02511.86170.9962-91.4613
Cytotoxic6.682427.545720Partial curve; partial efficacy; poor fit-5.17512.25260.861-25.54572-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.28819.49086.5142-4.21044.75951.44771.72043.2832-0.4826-3.55211.5616-1.0976-1.442-21.2425-19.2902-26.2881QC'd by BIOMOLInactive03.24750.9525-18.8964
Cytotoxic23.710193.126841Partial curve; high efficacy-4.62513.92950.9489-91.0412.0858-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.2443-3.1984-0.199713.89730.60014.4648-8.30652.45650.811-0.2967-0.07760.088610.98955.4259-31.5062-85.2443QC'd by BIOMOLCytotoxic29.8493108.411840Partial curve; high efficacy-4.52514.0950.9921-108.5943
Inactive02.24810.5195-8.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 112.5751-5.85510.12813.73894.13328.24181.27954.25414.65918.42590.13073.147412.08273.9666.749912.5751QC'd by ART-CHEMInactive02.25260.48479.5
Cytotoxic9.439234.203321Complete curve; partial efficacy-5.02513.1320.894-32.31981.8834-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.61375.31591.7117-0.85858.78-0.0810.7177-0.76264.06551.1951-4.8016-3.6366-0.459-14.2043-30.7093-31.6137QC'd by MicrosourceCytotoxic26.603248.471820Partial curve; partial efficacy-4.57512.53340.9934-48.0851
Inactive04-16.177-0.1697-9.1792-4.21641.9066-5.3806-0.96160.4121-5.1331-3.3638-0.05870.4161-5.1357-5.4857-1.2925-16.177QC'd by TocrisInactive04.44950.918310
Cytotoxic10.590985.872682Complete curve; high efficacy-4.97513.92950.9788-84.34711.5254-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.19184.19197.6194-2.25542.112711.554-1.9447-0.363-1.4443-5.1393-0.2045-0.4497-1.9204-25.8199-80.5151-83.1918QC'd by BIOMOLCytotoxic18.8336109.803841Partial curve; high efficacy-4.72512.33320.9775-108.1925
Inactive0410.93317.2308-0.76461.9030.8854-12.36610.0538-0.03730.03780.85910.1617-0.68821.54178.41924.24810.9331QC'd by DPISMRInactive02.40640.437310
Inactive03.92950.545916.5-1.032140 0 0 0 0 0 0 0 0 0 0 0 0 0 015.0573-1.0016-2.8234-2.88181.553-4.404-7.94341.5739-2.1443-4.82762.255.35516.2847-6.12956.377615.0573QC'd by TimtecInactive00.70.44975.5
Cytotoxic29.8493110.252640Partial curve; high efficacy-4.52512.30310.9779-109.67690.5757-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-83.08850.20916.1543-0.0464-5.63920.8022-1.55-1.65864.52973.84694.02740.9875-0.3079-12.105-32.034-83.0885QC'd by SigmaAldrichCytotoxic23.7101107.138841Partial curve; high efficacy-4.62513.1320.9922-106.8899
Cytotoxic4.216370.168183Complete curve; high efficacy-5.37511.82650.9542-75.4788-5.3107-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-66.79042.2008-11.44290.78810.9581-3.3197-4.8289-11.2303-7.4383-13.5817-10.6197-19.4834-33.1317-70.7599-75.9063-66.7904QC'd by SigmaAldrichCytotoxic6.682485.17583Complete curve; high efficacy-5.17512.25260.9899-85.1455
Inactive040.61421.36820.7153-0.4571-0.0959-0.8039-4.1432-4.6019-4.3611-0.5841.49151.5429-6.74321.21242.11860.6142QC'd by Toronto ResearchInactive0
Inactive02.24810.6569-25.4435040 0 0 0 0 0 0 0 0 0 0 0 0 0 1-6.9489-9.0935-1.1970.4962-0.2828-0.2884-0.6514-0.4859-0.9558-0.834612.2159-0.8399-4.0992-10.64-20.7863-6.9489QC'd by MicrosourceInactive03.990.9151-12.2781
Cytotoxic11.883290.050282Complete curve; high efficacy-4.92512.47290.973-88.31971.7305-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.10032.5615-9.7822-0.0524-0.0447.70862.0062.3996-2.72396.63640.75558.2888-9.0916-27.0183-69.093-87.1003QC'd by SigmaAldrichCytotoxic16.7855111.787642Partial curve; high efficacy-4.77512.25260.9888-110.5514
Inactive045.64962.63765.96770.68332.59292.6537-0.6376-1.73942.60582.96495.1854-1.38641.1535-2.51674.08825.6496QC'd by MicrosourceInactive0
Cytotoxic0.013384.417393Complete curve; high efficacy-7.87513.06540.9777-79.41735-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-65.1036-0.246612.5138-0.0588-0.1182-44.5452-81.5515-76.6214-76.487-79.8263-80.1839-83.5104-84.3071-81.9727-77.6097-65.1036QC'd by SigmaAldrichCytotoxic0.018881.862693Complete curve; high efficacy-7.72513.1320.9924-80.8961
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: MMP852
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL/well were dispensed into black, clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific) dispenser. The assay plates were incubated for an overnight at 37 C to allow cells to attach to the wells, followed by the transfer of 23 nL compound or DMSO vehicle by a pin tool (Kalypsys). The plates were incubated for 1 hr at 37 C and 5% CO2, followed by the addition of 5 uL of 2X m-MPI dye into each well using Flying Reagent Dispenser (Aurora Discovery) and then CellTiter-Glo reagent was added at 4 uL/well and incubated 30 min at room temperature. Then luminescence intensity was quantified on a ViewLux CCD-based plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000621652 uM-Replicate_1Activity at 0.0001398438 uM-Replicate_1Activity at 0.0003042657 uM-Replicate_1Activity at 0.0006604774 uM-Replicate_1Activity at 0.00120 uM-Replicate_1Activity at 0.00268 uM-Replicate_1Activity at 0.00598 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.066 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.330 uM-Replicate_1Activity at 0.735 uM-Replicate_1Activity at 1.635 uM-Replicate_1Activity at 3.629 uM-Replicate_1Activity at 8.077 uM-Replicate_1Activity at 17.94 uM-Replicate_1Activity at 39.08 uM-Replicate_1Activity at 83.25 uM-Replicate_1Activity at 95.27 uM-Replicate_1Activity at 256.5 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.95490.6668303.93240 0 0 0 0 0 0 0 0 0 0 0 0 0 114.3874-0.05674.78594.66550.70823.314420.946903.84678.92376.40017.2038026.807628.373414.3874QC'd by "NCI"Inactive0
Inactive00.70.5795-8.19027.540 0 0 0 0 0 0 0 0 0 0 0 0 0 126.28941.904211.57771.4338-0.33553.4577-9.8374-1.6222-1.294-9.6945-9.0786-9.77190-9.9186-11.408526.2894QC'd by "NCI"Inactive0
Inactive04.95490.3561-1.2895840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.9080.68331.905622.292.63590.03680.8244-3.2686-1.123-0.0614-3.5031-0.18361.43210.87850.6982-6.908QC'd by "NCI"Inactive0
Inactive03.06540.731714.5-1.240340 0 0 0 0 0 0 0 0 0 0 0 0 1-3.851-0.1635-1.0139-0.2437-5.6006-8.11692.28014.5084-0.5415-1.9632-3.21371.705312.296913.4035-3.851QC'd by "SigmaAldrich"Inactive0
Inactive01.88510.7417-0.938815.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.058814.864412.24359.43592.03060.061-2.2579-1.4637-3.2253-3.0996-4.53239.1724-3.68151.7625-1.1654-2.0588QC'd by "NCI"Inactive03.1320.3121-3.126
Inactive01.3310.6629-12.9936-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.02882.07910.1105-2.7873-1.66347.1249-4.84-1.3314-0.5713-4.2956-1.7646-2.2663-10.6661-7.0012-16.6613-10.0288QC'd by "NCI"Inactive0
Inactive02.33320.4499-7.62773.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.35654.78513.38265.3076.21690.26076.49632.7144-5.84079.15541.47333.92333.5491.4857-3.7073-6.3565QC'd by "NCI"Inactive0
Inactive03.57220.45020.699712.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.91749.94032.24144.2281-6.08360.0721.67432.88152.1391-0.82083.281.5489-2.2038-0.62853.8612.9174QC'd by "NCI"Inactive0
Inactive03.62720.614623.5-0.265740 0 0 1 0 0 0 0 0 0 0 0 0 0 019.3632-0.6601-7.7214-0.057163.73360.10252.21486.0528-4.65797.3773.3081-4.6226-3.7671.25074.404419.3632QC'd by "NCI"Inactive0
Inactive04.44950.909-17.158-1.540 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9739-0.882-0.6655-4.5070.1351-3.1899-0.7395-1.2264-1.79240.2923-2.9313-0.2798-8.3384-16.7983-7.9739QC'd by "Labotest"Inactive0
Inactive01.96730.44684-1.939340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.22170.0802-0.65570.811.0572-7.0327-4.99321.3493-5.0615-0.29654.74771.01351.6924.76685.4668-5.2217QC'd by "NCI"Inactive03.06540.33666
Inactive046.74843.236610.1577-1.69943.182719.73683.578-3.435917.42311.58818.26593.60072.83290.32262.32756.7484QC'd by "NCI"Inactive03.06540.738117
Inactive04.95490.41284.5-2.232340 0 0 0 0 0 0 0 0 0 0 0 0 0 07.89631.0579-6.4436-5.65627.3977-3.445-4.068-5.9011-0.93366.4726-0.23356.1832.5838-0.06286.84787.8963QC'd by "NCI"Inactive0
Cytotoxic33.491553.673920Single point of activity-4.47514.95490.9665-54.021-0.347-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.3868-3.3009-3.443-2.0818-1.0124-1.23580.2159-0.9523-1.6616-0.6518-0.44270.37690.73180.60971.0836-47.3868QC'd by "NCI"Cytotoxic33.491553.223520Single point of activity-4.47514.95490.7223-46.2235
Inactive045.66235.102117.44631.20376.07119.57515.30170025.48535.56410023.339713.00635.6623QC'd by "NCI"Inactive03.06540.44013
Inactive043.58878.2696-1.963.65083.624-6.63253.34710.93470.42242.51787.85661.10124.91355.28282.99883.5887QC'd by "NCI"Inactive04.95490.5056-1.8074
Inactive010.5009181.186640 0 0 0 0 0 0 0 0 0 0 0 0 0 013.8272-1.9278-0.236-1.0401-1.3264-1.72661.16427.6624013.456802.13708.347913.10213.8272QC'd by "NCI"Inactive04.95490.60960.5643
Inactive044.24861.72139.11043.81321.56561.3607-1.28352.40213.88820.89071.80965.00680.68390.04282.95714.2486QC'd by "Chembridge"Inactive0
Inactive02.72020.4076-6.4657440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.88814.273311.92621.70126.6392.7651-5.1669-0.49730.00335.90612.753413.2268-0.9486-4.6797-4.0598-7.8881QC'd by "NCI"Inactive0
Inactive01.59360.5107-18.5821240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.1517-0.7668-0.4846-0.3112-0.152-0.4145-0.13655.441412.6112-0.50271.19685.6539-2.5746-0.014-4.6704-12.1517QC'd by "NCI"Inactive02.33320.3476-4.374